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I.  INTRODUCTION 
 
A.  Overview 
Dopamine, a major neurotransmitter in the mammalian central nervous 
system, is involved in the control of locomotor activity, and also in pathways 
regulating behavior and reward (Schultz, 2002).  The dopamine transporter 
(DAT) plays a critical role in the synaptic clearance of dopamine by mediating the 
reuptake of dopamine from the extracellular space.  Following the invasion of the 
nerve terminal by an action potential (in dopaminergic neurons), dopamine is 
released into the synaptic cleft by Ca2+-mediated exocytosis.  The released 
dopamine binds to receptors on the postsynaptic membrane and activates 
dopaminergic signal transduction pathways.  The neurotransmission of dopamine 
is terminated primarily by reuptake of dopamine into the presynaptic cell via the 
dopamine transporter (Fig. 1).  Thus, DAT is, in part, responsible for the 
maintenance of dopaminergic homeostasis in neuronal cells.  The dopamine 
transporter belongs to a large class of transporters referred to as Na+/Cl--
dependent transporter or neurotransmitter: sodium symporter (NSS) family.  
Members of this class include: the serotonin transporter (SERT), norepinephrine 
transporter (NET), epinephrine transporter (ET), and also transporters for 
betaine, creatine, GABA, glycine, proline, and taurine (Amara and Arriza, 1993; 
Amara and Kuhar, 1993).  For these transporters, the reuptake process involves 
the translocation of substrate and cosubstrates Na+ and Cl- across the plasma 
membrane.  This transport process also involves a conformational change in the 
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transporter protein (Rudnick and Clark, 1993).  In the case of DAT, the outward-
facing transporter binds one Cl- and two Na+ ions and one dopamine molecule.  
These binding events permit the transporter to undergo a conformational change 
to an inward-facing conformation.  This internal-facing form dissociates Na+, Cl-, 
and dopamine to the cytoplasm.  On binding internal K+, the transporter 
undergoes another conformational change (to an outward-facing conformation) 
which allows the carrier to dissociate K+ on the cell exterior.  Consequently, the 
original form of the transporter is generated which can then initiate another round 
of transport by binding external Na+, Cl-, and dopamine.   
DAT is expressed almost exclusively in dopaminergic neurons of the 
substantia nigra and the ventral tegmental area of the brain (Ciliax et al., 1995; 
Freed et al., 1995).  The areas of the brain where dopaminergic neurons are 
found to project include the striatum, nucleus accumbens and the prefrontal 
cortex.  DAT is also expressed throughout the cell on axons, dendrites and the 
soma (Nirenberg et al., 1997).   
DAT is the primary target of psychostimulant drugs including 
methylphenidate, cocaine, and amphetamines; such drugs bind to DAT and 
inhibit the reuptake of dopamine (Kuhar et al., 1991).  Thus, a convincing clinical 
rationale exists for understanding the structure and function of this transporter 
protein.  In addition to inhibiting uptake of extracellular dopamine, amphetamines 
also stimulate efflux of intracellular dopamine (Jones et al., 1998).  The resultant 
effect of psychostimulant drug action on DAT is increased accumulation of 
dopamine in the synaptic cleft causing potentiated neurotransmission of 
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dopamine in those areas of the brain associated with reward and reinforcement.  
Consequently, the motor and reward pathways of the midbrain are activated, 
triggering the increased locomotor activity and euphoria associated with 
psychostimulant drug use.   
 
 
Figure 1.  Schematic representation of dopamine synaptic terminal.   
DAT is localized to presynaptic sites where it is vital for the termination of dopaminergic 
neurotransmission and maintenance of presynatic dopamine storage.  DA, dopamine; AMPH, 
amphetamine; DAT, Dopamine transporter; BZT, benztropine. 
 
Experiments using mice lacking the dopamine transporter have 
demonstrated the importance of the transporter in psychostimulant action (Giros 
et al., 1996).  High doses of cocaine did not increase locomotor activity above the 
already elevated levels in these DAT knock-out mice.  Nonetheless, it is pertinent 
to note that not all the behavioral effects of cocaine can be ascribed solely to 
DAT.  Subsequent studies evaluating both cocaine self-administration (Rocha et 
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al., 1998) and conditioned place preference (Sora et al., 1998) in DAT knock-out 
mice showed that cocaine self-administration and conditioned place preference 
were intact.  Mice with a double disruption of both dopamine and serotonin 
transporter genes exhibited no conditioned place preference in response to 
cocaine.  The serotonin transporter may contribute to cocaine reward and 
reinforcement naturally (Sora et al., 2001) or in compensation for the absence of 
DAT. 
 
B.  Statement of the problem 
Cocaine abuse is growin .S.  It is estimated that g at an alarming rate in the U
more than 23 million people in the U.S. have tried cocaine, nearly 40,000 people 
use it daily, and 5,000 new users are added each day (SAMHSA, 1997).  Drug 
abuse generally inflicts severe medical, social, and judicial costs upon the 
society.  The central problem with cocaine addiction is that even after treatment 
and extended periods of abstinence the risk of relapse is high.  The primary 
feature of cocaine addiction is the compulsive seeking of the drug that results in 
failure to resist taking the drug.  The abuse liabilities of cocaine result from its 
euphorigenic and reinforcing properties.  Neurochemical studies on effects of 
cocaine show that the mesolimbic and mesocortical dopamine systems of the 
brain are involved in psycholocomotor stimulant reward function.  The behavioral 
profile that is associated with cocaine addiction results from the accumulation of 
dopamine in the synapse and its actions at one or more of the D1- D5 dopamine 
receptors.  Thus, the reinforcing property of cocaine is caused by potentiated 
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neurotransmission of dopamine in mesolimbic pathways.  Cocaine binds to the 
dopamine transporter and inhibits dopamine reuptake leading to a distortion in 
dopamine homeostasis.  No definitive information exists on the conformation of 
neurotransmitter transporter proteins, as no crystallographic or high resolution 
data are available.  At present the binding sites for dopamine or cocaine on DAT 
have not been well elucidated.  Using site-directed mutagenesis and chimeric 
studies, investigators have identified certain amino acid residues in the primary 
structure of the dopamine transporter that are important for substrate and/or 
inhibitor binding to DAT.  Of the several DAT mutants published so far, aspartate-
79 (D79) of the rat DAT is still the only residue whose mutation caused an 
increase in both Km for dopamine uptake and Ki for dopamine to compete for the 
cocaine analog [3H]WIN35,428 binding site (Kitayama et al., 1992).  This 
suggested a critical role for D79 in DAT function.  In a separate study, Barker and 
coworkers (1999) showed that in both human norepinephrine and rat serotonin 
transporters, the replacement of the aligned aspartates with uncharged amino 
acids resulted in the disruption of substrate transport.  For the reason that 
dopamine and cocaine possess a protonated nitrogen atom at physiological pH, 
it was postulated that the positively charged amino group of dopamine or 
protonated nitrogen of cocaine directly interacts with the negatively charged 
carboxylate of D79 and that ionic competition between cocaine and dopamine is 
the mechanism of cocaine inhibition of dopamine uptake (Carroll et al., 1992).  
Several lines of evidence, however, directly contradict this hypothesis.  In their 
studies with neutral 8-oxa analogs of WIN35, 428 and cocaine, Madras et al. 
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(1996) and Kozikowski et al. (1999) have proven that both compounds are quite 
potent inhibitors of dopamine transport by DAT relative to the charged, nitrogen-
based parent compounds.  Nevertheless, the D79 residue appears to be crucial 
to DAT function.  The D79 residue is one of two charged residues that reside in 
the hydrophobic lipid bilayer.  Furthermore, amino acid sequence alignment of 
transmembrane domain 1 from various members of the NSS transporter gene 
family, which the DAT belongs to, shows that an aspartic acid at this position is 
conserved only in those members whose substrates have an aromatic moiety.  It 
is likely that the role of the D79 side chain may be to contribute to an aromatic 
binding pocket for DAT ligands.  Therefore, the primary focus of this study was to 
determine whether D79 was involved in the recognition of some feature of the 
DAT substrate or inhibitor structure.  The specific hypothesis to be tested here is 
that the D79 residue is pivotal to DAT function and that the side chain of this 
residue may form intramolecular contacts that supported an aromatic binding 
pocket.   
 In the course of this study using mammalian cell lines stably-transfected 
with WT DAT cDNAs, it was observed that the dopamine uptake inhibition 
potency (DUIP) of a given inhibitor will fluctuate even though the apparent 
binding affinity of the drug remained static.  The nature of this phenomenon was 
investigated by examining three possible influences on DAT function at the level 
of the cultured cell: the age of the cell line (measured by cell passage number), 
the density of the cell monolayer (i.e., percent confluence), and the effect of 
varying DAT expression level by manipulation of transfection conditions.  The 
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specific hypothesis to be tested in this case is that the DUIP of DAT inhibitors in 
CHO cells stably transfected with WT DAT fluctuate as a function of cell state.  
   
C.  Literature Survey 
1.  Structure of the Dopamine Transporter 
acids in its primary sequence.  As 
mentio
The human DAT contains 620 amino 
ned earlier, the three-dimensional structure of DAT, or any other member 
of the family of mammalian neurotransmitter transporters, is unknown due to the 
absence of X-ray crystallographic or high-resolution structural information.  
Nevertheless, the topological assignment of the dopamine transporter has been 
made possible by the use of analytical techniques such as substituted cysteine 
accessibility method (SCAM), site-directed mutagenesis, and hydrophobicity 
studies.  Hydrophobicity analysis of the primary sequences of mammalian 
monoamine transporters indicates that monoamine transporters are polytopic 
membrane proteins containing 12 transmembrane domains connected by 
alternating extracellular and intracellular loops with the N- and C-termini located 
in the cytosol (Fig. 2).  The cytoplasmic location of N-terminal and the 
extracellular location of the sequence between transmembrane (TM) domain 3 
and 4 of DAT has been demonstrated (Nirenberg et al., 1996).  In addition, the 
topological assignments of four cysteine residues have been verified using 
SCAM analysis (Ferrer and Javitch, 1998).  C90 and C306 are located 
extracellularly, and C135 and C342 appear to be intracellular (Ferrer and Javitch, 
1998).  Furthermore, three residues (two histidines and on glutamate) predicted 
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to be on the extracellular face of the human dopamine transporter, H193 (located 
in extracellular loop 2), H375 (located in TM 7), and E396 (TM 8), have been 
shown to constitute three coordinates of an endogenous Zn2+-binding site.  The 
participation of these residues in binding the small Zn2+ ion implies a nearness of 
extracellular loop 2, TM 7, and TM 8 in the tertiary structure of the human DAT 
(Norregaard et al., 1998; Loland et al., 1999).  DAT is a heavily glycosylated 
protein with an apparent molecular mass of ~80 kDa as determined by gel 
electrophoresis.  The N-deglycosylation of mature DAT reduced the molecular 
mass to ~50 kDa (Patel, 1997).  The bulk of cloned dopamine transporters have 
at least three consensus sites for N-linked glycosylation in the second 
extracellular loop located between TMs 3 and 4.  Mutational studies have shown 
that this glycosylation is very important for the activity and stability of the 
transporters at the surface, but does not seem to be important for the regulation 
of the intrinsic transport activity (Torres et al., 2003).  The stability and targeting 
of the human norepinephrine transporter to the cell surface largely depend on 
glycosylation of the transporter at the consensus sites (Melikian et al., 1996).  
This effect may also be applicable to the dopamine transporter protein.  
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        Figure 2.  Schematic illustration of plasmalemmal monoamine transporters topology. 
 
wo cysteines (C180 and C189) in the second extracellular loop are 
predict
rylated in stably expressing cells and striatal 
synapt
 
T
ed to form a disulfide bridge important to DAT cell surface expression 
(Wang et al., 1995).  Substitutions of these cysteines severely decreased the 
expression of the mutant transporters.  Immunocytochemistry data showed that 
COS cells transfected with C180A and C189A mutant DAT displayed reduced 
membrane staining and prominent staining in perinuclear regions consistent with 
Golgi apparatus (Wang et al., 1995).  These results suggest that cysteines in the 
DAT second extracellular loop may provide sulfide residues crucial to full 
transporter expression.   
DAT is phospho
osomes (Vaughan et al., 1997). Protein kinase C-mediated DAT 
phosphorylation (Vaughan et al., 1997) causes internalization of the transporter 
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protein (Pristupa et al., 1998; Melikian and Buckley, 1999) and down-regulation 
of transporter activity (Kitayama et al., 1994; Vaughan et al., 1997; Zhang et al., 
1997).  There are several DAT consensus sites for protein kinase 
phosphorylation (Giros et al., 1992); nonetheless, DAT function does not appear 
to be regulated by phosphorylation at these sites.  Deletion of all possible protein 
kinase C sites did not affect the ability of protein kinase C activators or inhibitors 
to regulate dopamine transport (Granas et al., 2003).  It is possible, therefore, 
that direct dopamine transporter phosphorylation might occur at nonconsensus 
phosphorylation sites. It is also likely that DAT phosphorylation is considerably 
influenced by ligand occupancy.    
 
2.  Substrate and Inhibitor Selectivity of the DAT 
chieved for several species 
(Giros 
syndrome.  A brief description of selected DAT inhibitors is given below. 
DAT cloning and characterization has been a
et al., 1991, 1992; Miller et al., 2001; Jayanthi et al., 1998; Kilty et al., 
1991; Usdin et al., 1991; Porzgen et al., 2001; Gallant et al., 2003; Shimada et 
al., 1991).  The DAT has a well-defined and distinctive pharmacological profile.  
Dopamine uptake by DAT is inhibited by a variety of compounds including the 
psychostimulants cocaine, mazindol, and methylphenidate, and a few selective 
compounds that include the GBR compounds 12909 and 12935 and the 
muscarinic antagonist benztropine.  In addition to clearing dopamine, DAT can 
transport amphetamines and the dopaminergic neurotoxin 1-methyl-4-
phenylpyridinium ion (MPP+), which triggers a Parkinson’s disease-like 
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   Benztropines 
Benztropine (3α-diphenylmethoxytropane, cogentin1) is a tropane-based 
linergic agent which is used for the 
treatment of symptoms associated with Parkinson’s disease.  Benztropine is 
different from cocaine by possessing a diphenylmethoxy group attached to the C-
3 position of the tropane ring.  Para-substitution of a halogen-group on one of the 
phenyl rings of benztropine augments its potency for inhibition of dopamine 
uptake.  It has been shown that optimal binding affinity at the DAT was 
accomplished when small halogens such as fluorine and chlorine were placed in 
the para- and/or meta- positions of one or both phenyl rings.  This modification 
caused a diminution in potency for inhibition of serotonin and norepinepherine 
uptake, resulting in a considerably more dopamine-selective compound than the 
parent benztropine.  The following structure–activity relationships for the 
benztropines have been established: the diphenyl ether must be in the α-
stereochemistry and both aryl rings are required and must be free to rotate.  
Assessment of benztropine analogs in animal models of cocaine abuse 
demonstrated that regardless of binding to DAT with high affinity and exhibiting 
potent inhibition of dopamine uptake, in vitro, these compounds did not 
demonstrate a cocaine-like behavioral profile (for a review of the structure-activity 
studies of benztropine analogs, see Newman and Kulkarni, 2002). 
 
dopamine uptake inhibitor.  It is an anticho
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                               Benztropine  
 
   GBR Compounds 
GBR compounds (aryl 1,4-dialkyl piperazines) were modeled after 
benztropine. The key structural dissimilarity between benztropine and GBR 
compounds is that the GBR compounds have a piperazine ring in place of the 
tropane nucleus present in benztropine.  One of the most potent compounds in 
this group is GBR 12909.  In contrast with cocaine, GBR 12909 is not a central 
nervous system stimulant.  The mechanism of action of GBR 12909 is identical to 
that of cocaine.  GBR 12909 binds to DAT and inhibit dopamine uptake.  GBR 
12909 differs from cocaine in that it produces a relatively moderate and long-
lasting increase in dopamine, which does not produce the same degree of 
euphoria compared to the effect of cocaine.  
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   Mazindol  
Mazindol is a dopamine uptake inhibitor with very low abuse liability.  
Currently, mazindol, 5-(4-chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-
a]isoindole, is marketed in the United States as an anorexic agent (exogenous 
obesity) and as an orphan drug for the treatment of Duchenne muscular 
dystrophy.  It is an effective inhibitor of uptake and binding at DAT, NET and 
SERT sites.  It blocks the uptake of dopamine and also inhibits [3H]cocaine and 
[3H]WIN 35,428 binding.   
 
                                  
 
   WIN-type of compounds 
 The key structural feature of phenyltropanes (WIN-type of compounds) is 
that they lack the 3α-benzoyl ester function group present in cocaine. The phenyl 
ring is directly attached to the tropane ring.  The phenyltropanes were first made 
with the intention of obtaining an effective stimulant or antidepressant with 
diminished toxicity.  These compounds bind to DAT and block dopamine uptake.  
WIN35,428 is the prototype compound in this class.  Inhibition of [3H]WIN35,428 
binding to the DAT is the common radioligand used to determine ligand binding 
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affinity due to sufficient specificity to DAT.  [3H]WIN35,428 labels both the high- 
and low-affinity binding sites of DAT, just like cocaine, and is resistant to 
metabolic and chemical degradation.  It also has a high signal-to-noise ratio. 
 
                                    
        
   4-ARA-127 
 4-ARA-127 is a piperidine-based ligand that has been fast-tracked by 
NIDA’s Medication Development Group for use as a substitute medication for 
cocaine dependence.  This compound displays the characteristics of a partial 
agonist at the dopamine transporter.  The most important pharmacological point 
of distinction between this compound and cocaine is its low activity at the 
serotonin transporter (with a slight action at other receptor systems as found 
through the NIMH screening program).  In primate studies,  it was established 
that this piperidine-based ligand was more weakly reinforcing than cocaine. 
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3.  Structure-Function Analysis of the Dopamine Transporter 
   a.  Transmembrane (TM) domains. 
 
    TM 1 
A TM 1 aspartic acid residue common to the plasma membrane 
monoamine transporters but not shared by other neurotransmitter: sodium 
symporter (NSS) family members is the side chain most frequently proposed to 
directly contact both inhibitors and substrates of the dopamine transporter.  Of all 
the several DAT mutants published so far, aspartate-79 (D79) of the rDAT is the 
only residue whose mutation (to glutamate) was reported to cause an increase in 
both Km for dopamine uptake, and an increase in Ki for dopamine in competing 
for the cocaine analog [3H]WIN35,428 binding site (Kitayama et al., 1992).  In 
contrast, recent findings with the same D79E DAT mutant showed no effect on 
dopamine affinity when compared with WT values.  Three-fold losses in cocaine, 
WIN 35,428, mazindol and methylphenidate affinities were observed, with little or 
no effect on the dopamine uptake inhibition potency (DUIP) for these drugs 
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(Wang et al., 2003).  On the other hand, binding affinities and DUIPs for 
benztropine and its analogs were altered substantially by the D79E mutation 
(Ukairo et al., 2005).  Barker et al. (1999) showed that for the human 
norepinephrine transporter (NET) and rat serotonin transporter (SERT), the 
replacement of the analogous aspartate residue with uncharged amino acids 
resulted in the disruption of substrate transport.  These findings led investigators 
to believe that the positively charged amino group of dopamine directly interacts 
with the negatively charged carboxylate of D79, an approach based on the G 
protein-coupled receptor model of a salt bridge between the positively charged 
agonist amino group and negatively charged TM domain carboxylate side chain 
(Strader et al., 1988).  Consequently, it has been postulated that ionic 
competition between cocaine and dopamine is the mechanism by which cocaine 
inhibited dopamine uptake (Carroll et al., 1992).  The neutral “8-oxa” analogs of 
WIN35,428 and cocaine still inhibit DAT, albeit less potently than the charged, 
nitrogen-based parent compounds (Madras et al., 1996 and Kozikowski et al., 
1999).  Thus, the idea that D79 of the plasma membrane dopamine transporter is 
a counter ion for the positively charged substrate amino group is speculative.  A 
glycine side chain is found at the analogous position in the other NSS family 
members including transporters for GABA, betaine, glycine and proline.  The 
substrates for these transporters share with the monoamines the positively 
charged amino group but lack aromatic groups (Wang et al., 2003).  The 
presence of an aspartic acid side chain at this position in only those transporters 
recognizing aromatic substrates may indicate that the aspartic acid residue 
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serves as a ‘strut’ supporting an aromatic binding site for the ligand (Ukairo et al., 
2005).  Recent data were not in agreement with, but did not rule out, formation of 
a salt bridge between aspartate and either dopamine, cocaine or amphetamine 
(Wang et al., 2003; Ukairo et al., 2005).  The aspartate (D75) in the analogous 
position in NET was intolerant to mutation, and like the DAT, only glutamate 
substitution of D98 yielded a functional SERT (Barker et al., 1999).  In an effort to 
find DAT TM residues capable of directly interacting with the positively charged 
moieties of substrates and inhibitors, conserved acidic and tryptophan hDAT 
residues were separately mutated and the mutant transporters characterized, 
including the TM 1 residues D68 and W84 (Chen et al., 2001).  The mutation of 
D68 to asparagine (D68N) resulted in 3 - 4 fold losses in affinity for WIN 35,428 
and in cocaine DUIP (Chen et al., 2001).  The mutation did not appreciably affect 
recognition of the classic DAT inhibitor GBR-12909 or most of the 
hydroxypiperidine GBR-like analogs tested; however, one such analog, (+)-R,R-
D-84, sustained a 17-fold affinity loss.  (+)-R,R-D-84 differs from one of the 
analogs unaffected by the mutation only in the position of a hydroxyl group.  
Thus, it is possible that DAT interacts with GBR analogs by way of hydrogen 
bonding between its D68 residue and the hydroxyl groups of these compounds 
(Zhen et al., 2004).    
Human (W84L) and rat (W84A) DAT substitutions of this tryptophan 
residue increased WIN 35,428 affinity and cocaine DUIP without affecting 
dopamine Km values (Chen et al., 2001; Lin et al., 2000).  It is envisaged that 
W84 may contribute to maintaining an intracellular-facing DAT conformation 
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(Chen et al., 2001).  The Na+-dependent conformational changes required for 
DAT function were impaired in hDAT W84L (Chen et al., 2004).  This mutant also 
displayed Na+ sensitivity differences between cocaine and the diphenylmethoxy-
bearing compounds benztropine and GBR-12,909.  Taken together with the 
aforementioned rDAT D79E results, the hDAT W84L findings suggest that TM 1 
residues may provide discrimination between diphenylmethoxy-bearing 
compounds and classic inhibitors such as cocaine, WIN 35,428 and mazindol.  
Moreover, of several endogenous hDAT cysteine residues surveyed for 
accessibility to the methanethiosulfonate alkylating agent MTSET, the 
benztropine-induced DAT alkylation pattern deviated from those of cocaine, WIN 
35,428, mazindol and dopamine only at C90, a residue immediately extracellular 
to TM 1 (Reith et al., 2001).  It is unclear whether these TM 1-associated inhibitor 
selectivities are solely due to DAT conformational differences or are indicative of 
TM 1 contributions to inhibitor binding sites. 
 
    TM 2 
Mutation of rDAT F98 to alanine (F98A), a residue presumed to be located 
at the TM 2 extracellular boundary, decreased WIN 35,428 binding 6-fold.  The 
mutation had no effect on the dopamine uptake affinity, but dopamine turnover 
rate was significantly diminished (Lin et al., 1999).  F98 is largely conserved in 
the NSS family and possibly less likely to directly contact specific uptake 
inhibitors.  A mouse/Drosophila DAT chimera study led to identification of mDAT 
F105 as the residue primarily responsible for the 10-fold higher DUIP of cocaine 
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at the mDAT; this position is occupied by methionine in the dDAT.  Of several 
mutations tested, only the presence of an aromatic side chain at mDAT position 
105 retained wildtype-like DUIPs for cocaine.  Substitutions of F105 with 
nonaromatic amino acids alanine, serine, threonine, leucine, isoleucine, 
asparagine, and glutamine resulted in mutants with diminished cocaine binding 
affinity.  Whether the effect of nonaromatic substitution of mDAT F105 on 
cocaine DUIP was direct or indirect was not investigated (Wu and Gu, 2003).  
Intriguingly, WIN 35,428 affinity at F105A mutant rDAT decreased by only 2-fold 
relative to wildtype rDAT (Lin et al., 1999).  In contrast with the observation made 
in the studies of DAT TM2, substituted cysteine accessibility method (SCAM) 
analysis of rSERT TM 2 did not identify residues that directly affected substrate 
binding or were accessible to alkylating agents (Sato et al., 2004).  Most recently, 
random mutagenesis of mDAT TM 2 residues in the vicinity of F105 generated 
the triple mutant L104V/F105C/A109V, which suffered 69- and 47-fold DUIP 
losses for cocaine and methylphenidate.  The DUIPs for the substrates 
amphetamine and methamphetamine at the triple mutant were not significantly 
different from those at the wildtype mDAT (Chen et al., 2005). 
 
    TM 3 
A region of the dopamine transporter surrounding the 3rd transmembrane 
domain is considered to be vital for cocaine recognition.  Using human/bovine 
DAT chimeras a 54 residue segment encompassing TM 3 was identified as 
especially crucial for dopamine uptake and WIN 35,428 binding (Lee et al., 
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1998).  Remarkably, replacement of the bDAT TM 3 residue I152 with its 
conservative valine counterpart in the hDAT was found to almost single-handedly 
confer the superior substrate transport and WIN 35,428 binding characteristics of 
the hDAT (Lee et al., 2000).  Two positions away, FI54 in TM 3 also appears to 
be a cocaine-selective residue in DAT.  Mutation of F154 to alanine (F154A) 
lowered cocaine affinity by about 10-fold while retaining normal dopamine uptake 
activity (Lin and Uhl, 2002).  The F154A mutation also altered cocaine 
stereoselectivity.  V152 and F154 should be located on opposite faces of DAT 
TM 3, implying that both cannot directly contact the ligand.  SCAM analysis of TM 
3 of rSERT indicated that I172, the residue analogous to hDAT V152, is on the 
helical face accessible to ligands and external agents (Chen et al., 1997).  
Moreover, I172 and Y176 of rSERT are in or near the binding sites for serotonin 
and cocaine (Chen et al., 1997; Chen and Rudnick, 2000).  Assuming that TM 3s 
of the DAT and SERT have comparable orientations in the plasma membrane, 
V152 would be expected to face the ligand pore and F154 would face the lipid 
bilayer.  F155 of DAT could still face the ligand pore, a residue conserved among 
DATs but replaced by tyrosine in SERTs and NETs.  The rDAT F155A mutant 
sustained a profound loss in apparent affinity for dopamine, but only a mild 
decrease in WIN 35,428 affinity (Lin et al., 1999). 
 
    TM 5 
Replacement of W267 hDAT with leucine forms a mutant DAT with a 3-
fold decrease in cocaine DUIP when compared with WT hDAT (Chen et al., 
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2001).  Uptake kinetics suggest that W267 contributes to an outward- 
(extracellular-) facing DAT conformation (Chen et al., 2001).  This residue is 
presumed to border the cytoplasm.  Glycine replacement of rDAT P272 modestly 
reduced Vmax for dopamine uptake, but decreased WIN 35,428 binding affinity 
10-fold without a reduction in rDAT plasma membrane expression.  DUIPs for 
cocaine, BTCP (1-[1-(2-benzo[b]thiopheneyl)cyclohexyl]piperidine hydrochloride),  
mazindol and trihexyphenidyl decreased by over 100-fold (Kopajtic, 1997).  A 
subsequent study characterized rDAT P272A mutant in uptake and binding 
studies.  The alanine mutant decreased the affinities for both dopamine and WIN 
35,428 binding relative to wildtype rDAT (Lin et al., 2000).  Alanine replacement 
of the analogous hNET residue P270 yielded undetectable specific binding of 
nisoxetine and 11-, 3- and 3-fold decreases in the norepinephrine uptake 
inhibition potencies (NUIPs) of nisoxetine, desipramine and cocaine, 
respectively.  Of 10 hNET proline residues mutated, only P270A decreased 
recognition of uptake inhibitors by 3-fold or more (Paczkowski and Bryan-Lluka, 
2004).  The number of TM proline residues is observed to be inexplicably large in 
transport proteins when compared with other integral membrane proteins, yet it is 
not clear how such TM proline residues affect transporter protein structure and 
function (Williams and Deber, 1991; Brandl and Deber, 1996).  In general, it has 
been postulated that proline residues disrupt α-helices, whereas alanine residues 
promote α-helix formation (Barlow and Thornton, 1988).  The extent of the α-
helical "kink" induced by proline, however, is reliant on its environment (Li et al., 
1996), and especially on neighboring residues (Ri et al., 1999; Visiers et al., 
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2003).  Thus, proline residues may serve a structural role in determining protein 
infrastructure by influencing helix-helix packing.  Functional roles for TM proline 
residues may include providing hinges that facilitate signal transduction, 
mediating conformational changes via cis-trans isomerization of the bond linking 
the proline to the preceding residue of the polypeptide, and providing a geometry 
that allows neighboring amide carbonyl oxygen atoms of the polypeptide to serve 
as cation binding sites (Sansom et al., 2000; Eisenman and Dani, 1987; Sansom, 
1992).  The latter functional role is most likely for the monoamine transporters.  
Thus, P272 may provide a direct ligand binding site, a key Na+ binding site that 
modulates transport or substrate or inhibitor recognition, or simply a kink 
necessary to the ligand or ion binding pocket. 
 
    TM 6 
Mutation of hDAT W311 to leucine (W311L) decreased WIN 35,428 
affinity 10-fold and cocaine DUIP over 3-fold while dopamine inhibition of WIN 
35,428 binding decreased by over 100-fold (Chen et al., 2001).  This mutation 
had no effect on the plasma membrane expression of hDAT.  Conversely, 
alanine replacement of the rDAT counterpart (W310A) increased WIN 35,428 
affinity 4-fold, and dopamine displacement of the cocaine analog was over 200 
times more effective (Lin et al., 2000).  The rDAT W310A mutation caused 
decreased plasma membrane expression, increased Km and diminished Vmax 
for dopamine uptake.  The discrepancy in the data obtained for hDAT and rDAT 
could be because the rDAT binding was conducted at 4oC, compared to 37oC in 
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the hDAT study (Chen et al., 2001).   Two residues away, the hDAT D313N 
mutant did not markedly affect WIN 35,428 or cocaine binding under normal 
assay conditions, and dopamine affinity was diminished (Chen et al., 2001).  
Although it is unlikely to be part of the substrate or inhibitor binding sites, D313 
may nevertheless regulate access to external dopamine in a Na+-dependent 
fashion.  This residue and W84 have been shown to be involved in cation 
interactions, and controls, in part, the ability of Na+ to drive the DAT between 
inward- and outward-facing conformations, in turn influencing dopamine access 
and Na+-dependent cocaine affinity (Chen et al., 2002; Chen and Reith, 2003).  
 
    TM 7 
Simultaneous mutation of the rDAT S356 and S359 residues to glycine or 
alanine resulted in reductions in WIN 35,428 binding affinity and decreases in 
dopamine uptake.  These residues are hypothesized to form hydrogen bonding 
interactions with the catechol hydroxyl groups of dopamine (Kitayama et al., 
1992).   This model was borrowed from that of Strader and colleagues, who 
demonstrated an association between α-adrenergic receptor TM serine residues 
and agonist hydroxyl groups (Strader et al., 1989).  The fact that a serine side 
chain is found at this same position throughout the NSS family, including 
transporters for non-catechol substrates, argues against this model. 
 Finally, alanine replacement of rDAT F361 decreased WIN 35,428 binding 
affinity by an order of magnitude without affecting dopamine uptake kinetics (Lin 
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et al., 1999).  Positioned at the midpoint of TM 7, this side chain is largely 
conserved in the NSS family. 
 
    TM 8 
For the rDAT, alanine substitution of W406 (W406A) decreased WIN 
35,428 binding affinity by 3-fold; decreased Vmax for dopamine uptake by ~10-fold 
and increased dopamine uptake and binding affinities.  DAT plasma membrane 
expression was altered in this mutant (Lin et al., 2000).  This residue is not far 
from the extracellular boundary and is largely conserved in the NSS family, 
although a phenylalanine side chain is found at the same position in the SERT. 
 
   b.  Extracellular loops (ECL)  
Many mutations of recognized extracellular and intracellular residues have 
been generated for the purpose of detecting conformational shifts in, or mapping 
tertiary structure of, NSS family members.  A few of these mutations were 
demonstrated to affect uptake inhibitor recognition.  The hDAT C90A mutant was 
prepared toward generating a DAT species lacking endogenous 
methanethiosulfonate-reactive cysteine residues (Ferrer and Javitch, 1998).  This 
mutation did not alter affinity for WIN 35,428, but selectively diminished the DUIP 
of benztropine; DUIPs of cocaine, WIN 35,428 and mazindol were unaffected by 
the mutation.  This very highly conserved ECL 1 residue is not expected to 
directly contact benztropine, but rather to differentially contribute toward 
stabilizing benztropine- versus cocaine-preferring DAT conformations (Reith et 
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al., 2000; Ferrer and Javitch, 1998).  Gether and colleagues have mutated many 
extratransmembranous hDAT residues in elucidating the endogenous Zn2+ 
binding site of the DAT, and in creating new Zn2+ sites toward mapping TM 
domain proximities (Loland et al., 2004; Norgaard-Nielsen et al., 2002; Loland et 
al., 1999).  In the course of this work, the extracellular hDAT mutants E218Q 
(ECL 2), E307Q (ECL 3) and D385N (ECL 4) were found to sustain 4- to 5-fold 
losses in WIN 35,428 affinity (Loland et al., 1999).  Treatment of M371C and 
A399C mutant hDATs with MTSET caused a profound reduction in [3H]dopamine 
uptake (Norregaard et al., 2003).  Cocaine, but not dopamine, protected A399C 
DAT from MTSET-induced inactivation.  On the other hand, dopamine, and not 
cocaine protected M371C from MTSET.  This observation may imply that A399 is 
in the DAT binding site of cocaine or that cocaine induces a conformational 
change that diminishes the reactivity of A399C.  In addition, the finding that 
protection of A399C occurs selectively with inhibitors and protection of M371C 
selectively with substrates supports the notion that inhibitors promote and bind 
conformational states of the transporter that differ from those adopted in the 
presence of substrates (Norregaard et al., 2003). 
 Regarding other ECL mutations, WIN 35,428 affinity decreased 5-fold as a 
result of the ECL 4 rDAT F390A mutation; dopamine uptake was virtually 
eliminated (Lin et al., 1999).  Asparagine substitution of hDAT D476, a residue at 
the ECL 5 / TM 10 border, decreased WIN 35,428 affinity 4-fold, cocaine DUIP 3-
fold, and apparent affinity (measured by Km value) for dopamine 7-fold (Chen et 
al., 2001).  For the above ECL loop mutants, it is likely that the inhibitor binding 
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affinity and uptake inhibition potency losses are due to mutation-induced 
conformational changes; however, modifications in the actual inhibitor binding 
sites have not been ruled out. 
 
   c.  Intracellular loops (ICL) 
The tyrosine residue at position 335 of the hDAT may be important for 
cocaine binding.  Mutation of this residue to alanine (Y335A) caused defects in 
the function of high affinity Zn2+ binding to DAT (Loland et al, 2002). Zn2+ binding 
to WT DAT normally reduces dopamine uptake.  In Y335A DAT, binding of Zn2+ 
to its high affinity sites resulted in potentiation of dopamine uptake.  In addition, 
Y335A mutation caused a 150-fold reduction in apparent affinity of DAT for 
cocaine and related inhibitors when compared with WT DAT values.  Loland and 
colleagues proposed that Y335 may be part of a network of intramolecular 
interactions that is important for stabilizing the transporter in a conformational 
state that maintains the structural integrity of the inhibitor binding site and to 
which extracellular substrate can bind and initiate transport.  Further analyses of 
the intracellular loops of hDAT identified other residues that, when mutated to 
alanine, exhibited similar phenotype as Y335A (Loland et al, 2004).  Akin to 
Y335A, the mutants K264A (IL2), D345A (IL3), and D436A (IL4) were 
characterized by lower affinities for cocaine and other inhibitors as well as a low 
uptake capacity that was potentiated by Zn2+.   In a separate study, Chen et al, 
2004 showed that D345N DAT also exhibited a phenotype similar to Y335A.  
D345N mutation decreased cocaine analog binding by over 90% but uptake 
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inhibition by various DAT inhibitors was preserved in contrast to what was 
observed with Y335A mutation. 
 
4.  Regulation of DAT Function 
   a.  Post-translational modification 
DAT function is regulated largely by way of rapid shuttling of DAT to and 
from the plasma membrane.  Phosphorylation of DAT by kinases leads to rapid 
redistribution and internalization of DAT away from the plasma membrane 
causing diminished cellular uptake of dopamine (Pristupa et al., 1998, Melikian 
and Buckley, 1999; Daniels and Amara, 1999).  There are several consensus 
sites on the primary structure of the DAT for protein kinase phosphorylation of 
the transporter (Giros et al., 1992).  Acute exposure of hDAT expressing Sf9 cells 
to  PMA, a PKC activator, reduced Vmax for [3H]dopamine uptake by ~ 40% 
when compared with control cells treated with αPDD (an inactive phorbol ester) 
(Pristupa et al., 1998).  This inhibition of uptake was blocked by the protein 
kinase inhibitor staurosporine (Pristupa et al., 1998).  Furthermore, confocal 
microscopy data revealed that the observed decline in [3H]dopamine uptake was 
associated with redistribution of surface DAT to the internal environment. 
Recruitment of the internalized transporters back to the cell surface was 
responsible for the observed augmentation in [3H]dopamine uptake in cells 
treated with the PKC inhibitor (Pristupa et al., 1998).   Nonetheless, proof that the 
direct phosphorylation of the transporter modifies its intrinsic activity or triggers 
the downregulation and internalization of the dopamine transporter is 
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inconclusive. The deletion of all the consensus sites for protein kinase C did not 
put a stop to protein kinase C-induced internalization (Chang et al., 2001).  In a 
different study, deletion of the first 22 amino acids (N-terminus) from DAT 
eliminated 32P incorporation into DAT in response to PKC activation (Granas et 
al., 2003).  This shortened mutant DAT still transported substrate and was 
internalized normally subsequent to protein kinase C activation (Granas et al., 
2003).  These data mean that N-terminal phosphorylation of DAT is not 
necessary for transporter internalization.  Recent evidence indicates that the 
transport capacity and intracellular trafficking of DAT is controlled by mitogen-
activated protein kinase (MAPK) (Moron et al., 2003).  Incubation of striatal 
synaptosomes or epitope-tagged hDAT HEK 293 cells with MAPK kinase 
inhibitors diminished dopamine uptake in a concentration dependent manner; 
decreased Vmax for dopamine uptake but had no effect on dopamine uptake 
affinity (Moron et al., 2003).  Biotinylation and confocal microscopic studies 
showed that the observed effect of MAPK kinase inhibitors on dopamine 
transport kinetics was due to clathrin-mediated redistribution of hDAT from the 
plasma membrane to the internal environment of the cell (Moron et al., 2003). 
It has been demonstrated recently that PKC can control MAPK activation 
and that the mechanism of activation shows isotype specificity (Schonwasser et 
al., 1998).  Some species of PKC, such as PKC-α, show an ability to activate the 
MAPK cascade via c-Raf, while other isoforms activate this cascade by a 
mechanism independent of c-Raf1 activation.  Thus, distinct subclasses of PKC 
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may account for two independent signalling pathways to MEK and, hence, MAPK 
activation. 
 
   b.  Protein-protein interactions 
Monoamine transporters have sequence motifs that are known to guide 
protein-protein interactions, including a leucine repeat in TM 2, a PDZ binding 
site at the extreme carboxyl termini, and presumed tyrosine-based and di-leucine 
internalization motifs (Torres et al., 2003).  By means of the yeast two-hybrid 
system, a direct interaction between α-synuclein and DAT has been determined 
(Lee et al., 2001).  α-synuclein is a pre-synaptic protein that has been associated 
with Parkinson’s disease (Gwinn- Hardy, 2002).  α-synuclein augments the 
functional activity of DAT when it is co-expressed with DAT in cells (Lee et al., 
2001).  On the contrary, coexpression of α-synuclein and DAT in Ltk– fibroblasts 
manifestly decrease the reuptake of dopamine by DAT by ~30–50% (Wersinger 
and Sidhu, 2003; Wersinger et al., 2003; Sidhu et al., 2004).  The diminution in 
DAT activity was due to a reduction in Vmax for dopamine uptake by the 
transporter without any change in DAT expression levels.  An outcome of the α-
synuclein-mediated reduction of DAT activity was that upon exposure of 
cotransfected cells to dopamine, there was decreased dopamine-induced 
oxidative stress and cytotoxicity.  In the presence of α-synuclein, the DAT was 
trafficked away from the plasma membrane into the cytoplasm.  This is evident 
from biotinylation experimental data showing reduced DAT presence at the 
plasma membrane by (Wersinger et al., 2003).  α-Synuclein interacts directly with 
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DAT, creating a stable protein: protein heteromeric complex in cotransfected 
cells, mesencephalic neurons, and substantia nigra. The interactions were 
observed between the nonamyloid β component (NAC) domain (residues 58-
107) of α-synuclein and the last 22 amino acids of the carboxyl terminal tail of 
DAT (Wersinger et al., 2003).  Analogous to wild-type, the missense A30P 
mutant form of α-synuclein decreased DAT function, trafficking DAT away from 
the plasma membrane and contributing to the formation of stable protein: protein 
complexes, again through the NAC domain (residues 58-107) of A30P and the 
last 22 amino acids of the CT tail of DAT (Wersinger et al., 2003a).  The other 
missense A53T mutant was unable to alter DAT function, and succeeding studies 
demonstrated that this protein interacted only weakly with the transporter 
(Wersinger et al., 2003a). 
 The PDZ domain-containing protein PICK 1 has been shown to interact 
with the carboxyl termini of DAT and NET (Torres et al., 2001).  In culture, PICK 
1 colocalizes with DAT and NET in dopaminergic and noradrenergic neurons 
respectively.  PICK 1 additionally stimulates DAT and NET clustering in 
transfected cells thereby increasing the activity of the transporters.  Thus, PICK 1 
may play a part in targeting of these transporters to the nerve terminals (Torres 
et al., 2001).  In cultured neurons, a DAT mutant lacking the PICK 1 binding site 
failed to localize to neuronal processes and remained confined primarily in cell 
bodies.  There are indications that PICK 1 interacts with PKC.  It is possible then 
that PICK 1 may be involved in the PKC-mediated trafficking of monoamine 
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transporters.  Recent experience also suggest an interaction between DAT and 
the LIM homeodomain-containing protein, Hic-5 (Carneiro et al., 2002).   
 
   c.  Transporter oligomerization 
The oligomerization of DAT has been well studied and there are indications 
that DAT function is also regulated via transporter oligomerization.  In 
mammalian cells co-expressing differentially tagged DAT molecules, HA-tagged 
DAT co-purified with 6His-tagged DAT signifying a physical contact between 
transporter proteins (Torres et al., 2003).  Verification of the functional 
oligomerization of DAT was achieved using dominant-negative mutants of DAT.  
Two loss-of-function mutant transporters (Y335A and D79G) that were expressed 
at the cell surface blocked wild-type DAT uptake activity without affecting the 
membrane targeting of the wildtype transporter.  Furthermore, non-functional 
amino and carboxyl termini-truncated mutants of DAT blocked wild-type DAT 
function by impeding the normal processing of the wild-type transporter to the cell 
membrane (Torres et al., 2003).  Mutations in the leucine repeat of the second 
transmembrane domain of the transporter removed the dominant-negative effect 
of all these mutants. Additionally, a small fragment comprising the first two 
transmembrane domains of DAT blocked wild-type transporter function but not 
when the leucine repeat motif was mutated. Taken together, these results 
indicate that the assembly of DAT monomers plays a vital role in the expression 
and function of the transporter (Torres et al., 2003).  Hastrup et al., 2001 have 
also identified a well characterized dimerization motif, GxxxG, in the intracellular 
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half of TM 6 of DAT.  DAT dimers are formed as a result of a symmetrical cross-
linking between cysteine residues located on the extracellular face of TM 6. The 
precise contribution of oligomer formation to transporter function remains 
uncertain.  Nonetheless, oligomerization has clearly been established to play a 
role in facilitating the trafficking of the transporters to the surface. Data from 
Javitch’s (Hastrup et al., 2001) and Caron’s research groups (Torres et al., 2003) 
have shown that mutants in which the domains involved in oligomer formation 
have been mutated are not efficiently delivered to the cell surface. 
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II.  MATERIALS AND METHODS 
 
A.  Materials and Equipment 
     1.  Facilities 
 Laboratories – Mellon Hall of Science, Room 456 
 Office – Mellon Hall of Science, Rooms 420 and 456 
2. Cell lines 
 Chinese Hamster Ovary (CHO) cells stably expressing wildtype and D79E  
 mutant DAT.   
 COS 7 cells 
3. Chemicals and Drugs 
 Bovine serum albumin 
 Fisher Scientific, Pittsburgh, PA 
 
 Complete Mini protease inhibitor cocktail tablets 
 Roche Diagnostics Corp., Indianapolis, IN 
 
 Compressed carbon dioxide 
 Air Products, Pittsburgh, PA 
 
 Dimethylsulfoxide 
 Sigma Chemical Co., St. Louis, MO 
 
 Ampicillin Na salt 
 Fisher Scientific, Pittsburgh, PA 
 
 Ethanol, HPLC grade 
 Fisher Scientific, Pittsburgh, PA 
 
 Isopropanol, DNase-free 
 Fisher Scientific, Pittsburgh, PA 
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 LB agar 
 Fisher Scientific, Pittsburgh, PA 
 
 LB broth 
 Fisher Scientific, Pittsburgh, PA 
 
 Methanol, HPLC grade 
 Fisher Scientific, Pittsburgh, PA 
 
 Ribonuclease A 
 Fisher Scientific, Pittsburgh, PA 
 
 Precast polyacrylamide gels, 4 – 20% 
 BioRad Laboratories, Hercules, CA  
 
 dNTP mix 
 Stratagene, La Jolla, CA 
 
 Plasmid mini-prep kit 
 Stratagene, La Jolla, CA 
 
 Polymerase, Pfu Turbo 
 Stratagene, La Jolla, CA 
 
 Quickchange mutagenesis kit 
 Stratagene, La Jolla, CA 
 
 XL1 Blue cells 
 Stratagene, La Jolla, CA 
 
 Dpn1 enzyme 
 Stratagene, La Jolla, CA 
 
 Plasmid maxi-prep kit 
 Qiagen Inc., Valencia, CA 
 
 Plasmid mini-prep kit 
 Qiagen Inc., Valencia, CA 
 
 Qiaquick gel extraction kit 
 Qiagen Inc., Valencia, CA 
 
 Qiaquick PCR extraction kit 
 Qiagen Inc., Valencia, CA 
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D-glucose 
 Sigma Chemical Co., St. Louis, MO 
 
 Tetracycline-HCL 
 Sigma Chemical Co., St. Louis, MO 
 
 F-12 Nutrient Mixture 
 GIBCO-BRL, Grand Island, NY 
 
 Glycine 
 Sigma Chemical Co., St. Louis, MO 
 
 HEPES 
 Fisher Scientific, Pittsburgh, PA 
 
 HRP-conjugated goat anti-rat IgG 
 Chemicon International, Temecula, CA 
 
 Agarose 
 Invitrogen, Carlsbad, CA 
  
 Alexa-Fluor 488, goat anti-rat IgG (H+L) 
 Molecular Probes, Eugene, OR 
 
 MAB369 Rat anti-Dopamine Transporter 
 Chemicon International, Temecula, CA 
 
 DH5α cells 
 Invitrogen, Carlsbad, CA 
 
 PolyFect Transfection Reagent 
 Qiagen Inc., Valencia, CA 
 
 SOC media 
 Invitrogen, Carlsbad, CA 
 
 Not 1 restriction enzyme 
 Invitrogen, Carlsbad, CA 
 
 Bgl2 Restriction Enzyme 
 Invitrogen, Carlsbad, CA 
 
 Psh1 restriction enzyme 
 Invitrogen, Carlsbad, CA 
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BsiW1 restriction enzyme 
 Invitrogen, Carlsbad, CA 
 
 Rhodamine phalloidin 
 Molecular Probes, Eugene, OR 
 
 T4 DNA ligase 
 Invitrogen, Carlsbad, CA 
 
 Penicillin-Streptomycin 
 GIBCO-BRL, Grand Island, NY 
 
 Fetal bovine serum 
 GIBCO-BRL, Grand Island, CA 
 
 Sodium Dodecyl Sulfate 
 Sigma Chemical Co., St. Louis, MO 
 
 Sodium Hydroxide 
Sigma Chemical Co., St. Louis, MO 
 
Trichloroacetic Acid 
Sigma Chemical Co., St. Louis, MO 
 
Trizma Base 
Sigma Chemical Co., St. Louis, MO 
 
Trypsin-EDTA 10X 
GIBCO-BRL, Grand Island, NY 
 
ScintSafe scintillation fluid 
Fisher Scientific, Pittsburgh, PA 
 
PBS, Ca/Mg-free 
Fisher Scientific, Pittsburgh, PA 
 
Tris-HCL salt 
Sigma Chemical Co., St. Louis, MO 
 
Protein MW marker 
Fisher Scientific, Pittsburgh, PA 
 
Sodium chloride 
Sigma Chemical Co., St. Louis, MO 
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[3H]WIN35, 428 
Perkin Elmer, Foster City, CA 
 
[3H]Dopamine 
Perkin Elmer, Foster City, CA 
 
GVA Mounting Solution 
Zymed, San Francisco, CA 
 
Goat Serum 
Biomeda, Foster City, CA 
 
4. Materials 
 
BioRad Protein Assay Kit 
BioRad, Hercules, CA 
 
Cryogenic vials 
Nalgene, Rochester, NY 
 
Polaroid Film 
Fisher Scientific, Pittsburgh, PA 
 
Pasteur pipettes 
Fisher Scientific, Pittsburgh, PA 
 
Scintillation vials 
Fisher Scientific, Pittsburgh, PA 
 
Test tubes, 12x75mm 
Fisher Scientific, Pittsburgh, PA 
 
PVDF membrane 
BioRad Laboratories, Hercules, CA 
 
Sterile Tissue culture plates (6-, 12-, 24-well) 
Fisher Scientific, Pittsburgh, PA 
 
Sterile disposable serological pipettes (5, 10, 25 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Eppendorf tubes (1.5µl) 
Fisher Scientific, Pittsburgh, PA 
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Glass microscope coverslips (#1) 
Fisher Scientific, Pittsburgh, PA 
 
Glass microscope slides 
Fisher Scientific, PA 
 
Kodak T-Max 400 film 
Eastman Kodak Co., Rochester, NY 
 
Fisherbrand Redi-TipsTM disposable pipette tips (1, 10, 200, 1000µl) 
Fisher Scientific, Pittsburgh, PA 
 
Pipette Aid 
Drummond Scientific Company, Broomall, PA 
 
5. Equipment 
 
Accumet pH meter, Model 291 
Fisher Scientific, Pittsburgh, PA 
 
BioRad Power Pac 3000 
BioRad, Hercules, CA 
 
Hot plate with stirrer 
Fisher Scientific, Pittsburgh, PA 
 
Leica Confocal Laser Microscope TCS-SP2 
Leica Microsystems, San Diego, CA 
 
Liquid Scintillation Counter Tri-Carb 2100TR 
Packard Instrument Co., Downers Grove, IL 
 
UV/VIS Spectrophotometer DU530 
Beckman Instruments, Fullerton, CA 
 
Analytical Balance 
Mettler-Toledo Inc., Highstown, NJ 
 
Centrifuge 5810R (Large) 
Eppendorf North America Inc., Westbury, New York. 
 
Centrifuge 5415C (Small) 
Eppendorf North America Inc., Westbury, New York. 
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Universal Vacuum System UVS400 
Savant Company Inc., Irvine, CA 
 
PCR Mastercycler 
Eppendorf North America Inc., Westbury, New York. 
 
Weighing Balance 
Denver Instrument, Denver, CO. 
 
Freezer (-20oC) 
Forma Scientific, Waltham, MS 
 
Liquid Nitrogen Tank 
 
Laboratory Refrigerator 
REVCO Thermo Electron Corporation, Asheville, NC. 
 
Horizontal Gel Electrophoresis System 
GIBCO-BRL, Grand Island, NY. 
 
Gel Apparatus 
BioRad, Hercules, CA. 
 
6. Computer Software 
 
GraphPad Prism 3.0 
GraphPad, San Diego, CA 
 
Microsoft Excel, Microsoft Office 2003 
Microsoft Corporation, Orem, UT 
 
Microsoft Word, Microsoft Office 2003 
Microsoft Corporation, Orem, UT 
 
Adobe Photoshop Version 5.0 
Adobe Systems, Seattle, WA 
 
Adobe Acrobat (Reader and Writer) 
Adobe Systems Inc., Seattle, WA 
MDL-ISIS Draw 2.5 
Elsevier MDL, San Leandro, CA 
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B.  Methodology and Procedures 
1.  Cell culture 
CHO-K1 cells stably transfected with WT DAT or D79E DAT were used in 
the present study.  These cells were grown at 37OC and 5% CO2 in F12K 
medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml 
penicillin, 100mg/ml streptomycin and 100µg/ml G-418.  COS-7 cells were 
employed for all experiments requiring transient transfection of plasmid DNA.  
The COS-7 cells were maintained in DMEM media supplemented with 10% FBS, 
100 units/ml penicillin, 100mg/ml streptomycin, and 20 mM L- glutamine.  All cells 
were grown in 75 cm2 flasks and subcultured twice weekly.  Cells were 
subcultured by aspirating media from the flask and washing the confluent 
monolayer with 10 mL Hanks buffered salt solution (HBSS).  The cells were then 
detached by addition of 3 mL trypsin-EDTA solution to the monolayer.  The 
trypsin-EDTA solution was swirled to coat the monolayer and 2 mL of the trypsin-
EDTA was aspirated from the flask.  The cells were left to stand at room 
temperature (under a sterile hood) in 1 mL trypsin-EDTA for 3 min or until the 
cells detach from the flask.  The trypsinization reaction was quenched by addition 
of 9 mL of appropriate “complete media” (media supplemented with FBS and 
antibiotics).  The trypsinate was gently mixed to create an even suspension of 
cells.  Two milliliters, out of a total volume of 10 mL, of the trypsinate was 
transferred into a new flask and 18 mL of “complete media” was added to it; the 
cell solution was then mixed gently.  The flask was capped and kept flat in the 
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incubator (37oC and 5% CO2) and cells were allowed to grow to confluence.  
Cells were typically subcultured on Mondays and Thursdays. 
 
2.  Site- directed mutagenesis 
All site-directed mutagenesis was conducted using the QuikChange 
mutagenesis kit (Stratagene).  rDAT in Bluescript vector was used as template 
for the PCR-based mutagenesis.  Sense and antisense oligonucleotides were 
designed to contain the desired mutations.  The oligonucleotide primers were 
synthesized by Sigma-Genosys Inc., U.S.A.  The sequences of primers used for 
the generation of D79L DAT were: 5’-
GTCATCGGCTTTGCTGTGCTCCTGGCCAATGTCTG-3’ for the forward primer 
and 5’-CCAGACATTGGCCAGGAGCACAGCAAAGCCGATGAC-3’ for the 
reverse primer.  These complementary primers were annealed to the template 
cDNA and extended with the proofreading polymerase pfu Turbo (Stratagene) 
with the following PCR parameters: 30 sec at 95oC, 30 sec at 95oC, 1 min at 
55oC, and 6 min at 72oC for 25 cycles.  Subsequently, the PCR product was 
digested with Dpn1 to eliminate the methylated, nonmutated parental strands.  
The mutant cDNA was then transformed into XL1-Blue supercompetent E. coli 
cells using the heat-shock method.  The bacterial cell solution was then plated on 
agar plates containing 50 µg/ mL ampicillin and incubated overnight at 37oC.  
The following day, colonies were selected and plasmid preparation was carried 
out using the Stratagene miniprep system to produce pure supercoiled plasmid 
DNA.  Mutagenesis was confirmed by DNA sequence analysis of the miniprep 
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product (University of Pittsburgh sequencing facility).  The fragment (~ 500 bp) 
containing the mutation in rDAT-pBluescript was isolated by digestion with Not1 
and Bgl2 restriction enzymes, gel purified, and ligated into the Not1/Bgl2- 
digested wild type rDAT-pC1 vector.  The ligation product was transformed into 
MC1061 cells using the heat shock method and cells were plated on agar plates 
containing ampicillin and tetratcycline and incubated overnight at 37oC.   
Colonies were again selected and the plasmid DNA was purified using the 
Stratagene mini-prep kit according to manufacturer’s guidelines.  The fragment 
containing the mutation in rDAT-pC1 was isolated by double digestion with 
PshA1 and BsiW1 enzymes.  This 1.8 kb fragment was then ligated into the 
PshA1/BsiW1- digested wildtype rDAT-pIRES vector.  The ligation product was 
transformed into DH5α supercompetent E. coli cells by way of the heat shock 
method and cells were plated on agar plates containing ampicillin.  The agar 
plates were then incubated overnight at 37oC to allow growth of bacterial 
colonies.  A few bacterial colonies were selected, lysed, and the supercoiled 
DNA was purified using the Stratagene mini-prep kit.  The presence of 
supercoiled plasmid DNA was verified by agarose gel electrophoresis.  Following 
confirmation of successful mutagenesis by DNA sequence analysis, a sample 
from the mini-prep product was again transformed into DH5α cells, plated on 
agar plates and incubated overnight at 37oC.  Plasmid preparations were carried 
out, this time, using the Qiagen maxi-prep kit to produce a larger volume of pure 
supercoiled plasmid DNA sufficient for transient transfection of cells.  The DNA 
concentration and purity (measured as A260:A280 ratio) were estimated by 
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spectrophotometric analysis.  Plasmid DNA having an A260:A280 ratio greater than 
or equal to 1.7 was typically used for transient transfection of COS 7 cells.  All 
other D79 mutant DATs used in the present study were previously generated by 
Wenfei Wang in the laboratory of Dr. Surratt at Albert Einstein College of 
Medicine (AECOM), Bronx, New York. 
 
3.  Cell Transfections 
A modification of the calcium phosphate method or the use of PolyFect 
reagent (Qiagen, Los Angeles, CA) was employed for transient transfections of 
COS 7 cells.  For the calcium phosphate method, confluent COS 7 cells were 
subcultured in 6-well plates such that the monolayer would be 40 - 50% confluent 
when the transfection commenced the next day.  Twenty micrograms of plasmid 
were used for the transient transfections.  Two tubes were prepared, with the 
contents of one tube slowly added to the second tube.  The first tube contained 
plasmid DNA, Millipore water, 10x Tris- EDTA (TE) buffer pH 8.0, and 0.5M 
CaCl2 mixed together to achieve a final amount of DNA of 20 µg.  The second 
tube contained 2x HEPES- buffered saline (HBS) solution.  The contents of the 
first tube were added to the second tube dropwise with continuous vortexing.  For 
an individual well of the 6-well plate containing 40% confluent cells, 200 µl of the 
above mixture was added.  The cells take up the exogenous plasmid via 
endocytosis of the calcium phosphate/DNA complex.  On the next day, the 
transfection mixture is removed and the replaced with 2 ml fresh DMEM. The 
cells were used for pharmacological studies 48 hours later.   
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For the PolyFect reagent-mediated transient transfection, a slight 
modification of the manufacturer’s protocol was employed.  The day before 
transfection, cells were seeded in 6-well plates and incubated overnight at 37OC 
and 5% CO2 such that the cells will be 50-80% confluent the next day.  On the 
day of transfection, cell monolayers in 6-well plates were washed with 1 x 1mL 
phosphate buffered saline (PBS), pH 7.3, and 1.5 mL of “complete” DMEM media 
was added to each well.  These cells were then incubated at 37oC and 5% CO2 
until the commencement of transfection.  The transfection mixture was prepared 
as follows: plasmid DNA (1.5 µg) was diluted with 100 µL of DMEM containing no 
serum, proteins, or antibiotics and mixed by vortexing for 10 seconds.  Ten 
microliters of PolyFect transfection reagent was then added to the DNA solution, 
mixed by vortexing for 10 sec, and incubated at room temperature for 8 min to 
allow DNA-PolyFect complex formation.  Subsequently, 600 µL of complete 
DMEM (containing serum and antibiotics) was added to the reaction tube 
containing the transfection complexes and mixed by pipetting up and down twice.  
The total volume of the transfection mixture was immediately transferred to a 
single well of the 6-well plate containing 80% confluent cells at room 
temperature.  The transfected cells were incubated at 37oC and 5% CO2 and 
used for pharmacological studies 48 hours after transfection.  When performing 
transient transfections of cells in more than one well (which was more often the 
case), the volumes described above were multiplied by the number of wells used. 
The stably-transfected DAT-CHO cell lines used in this study were 
prepared in the laboratory of Dr. Surratt at AECOM, New York.  Lipofectamine-
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mediated transfection was used to prepare the stable cell lines; stable 
transfectants were selected in the presence of 500 µg/ml G-418 in F-12K HAM 
medium.  Cell lines were maintained as described above. 
 
4.  Immunocytochemistry and confocal microscopy 
COS-7 cells were seeded on coverslips placed in 6-well plates and grown 
to 40 - 60% confluence.  Cells were transiently transfected on the following day 
with WT or D79 mutant DAT plasmids, or the vector control plasmid, using 
PolyFect reagent (Qiagen, Los Angeles, CA).  After 48 hours, cells were fixed in 
4% paraformaldehyde solution in PBS at room temperature for 15 min, rinsed 
once with PBS, and incubated with blocking-permeabilizing solution (5% goat 
serum, 1% BSA, and 0.1% Triton X-100 in PBS buffer solution) for 45 min at 
room temperature.  Cells were next incubated with rat monoclonal anti-DAT 
antibody (MAB369; Chemicon, Temecula, CA) at 1:1000 dilution for 1 hr.  The 
anti-DAT antibody solution was aspirated and cells were washed five times with 
PBS containing 0.1% Triton X-100 (TPBS), and incubated with a mixture of 
secondary antibody (goat anti-rat Alexa Fluor 488; Molecular Probes, Eugene, 
OR) at 1:500 dilution and rhodamine phalloidin (Molecular Probes) at 1:250 
dilution for 1 hr.  After three washes in TPBS followed by two washes in PBS, 
coverslips were mounted on slides using GVA mounting solution (Zymed, San 
Francisco, CA) and left to dry overnight in the dark at 4OC.  DAT protein was 
visualized using the Leica TCS-SP2 confocal laser microscope with a glycerin 
immersion 63x objective.  Alexa 488 was excited at 488 nm with an 
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argon/krypton laser and emission photons from 500 – 600 nm were accumulated 
by the photomultiplier tube.  Rhodamine phalloidin was excited at 543 nm with a 
helium/neon laser and emission photons from 550 to 650 nm were accumulated.  
The fluorophores were detected separately and overlay images were generated 
automatically by the imaging software. 
 
5.  [3H]-Dopamine saturation uptake assays 
All [3H]-dopamine uptake assays were conducted with cell monolayers 
seeded in 6-well plates.  In dopamine saturation uptake assays, cell monolayers 
in six-well plates were washed 2 X 1 mL with KRH buffer (25mM HEPES, pH 7.3, 
125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM KH2PO4, and 5.6 mM 
glucose) supplemented with 50 mM ascorbic acid (KRH/AA) and then incubated 
with increasing concentrations (0.5 – 16 µM) of a fixed ratio of [3H]dopamine: 
nonradioactive dopamine (~0.1 Ci/mmol) for 5 min.  Dopamine uptake was 
quenched by aspirating the dopamine solution and washing the monolayers with 
2 X 1 mL KRH/AA buffer. Subsequently, cells in each well were lysed with 1 ml of 
1% SDS, incubated at room temperature for 1 hr with gentle shaking, and 
transferred to scintillation vials for determination of incorporated tritium.  The 
results of liquid scintillation counting and protein determinations were used to 
calculate uptake of [3H]dopamine expressed as pmol/mg protein/ min.  In each 
experiment, the mean result from duplicate wells for each treatment was used 
and the experiments were repeated at least four times.  Specific uptake was 
calculated as the difference between uptake of [3H]dopamine in the absence and 
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presence of 10 µM mazindol.  KM and VMAX values were calculated from non-
linear regression analysis of the data for each individual experiment using the 
GraphPad Prism 3.0 software. 
 
6.  [3H]-Dopamine uptake inhibition assays 
The monolayer was washed twice with KRH/AA buffer (2 x 1 mL).  
Dopamine uptake inhibition experiments incubated the cells with inhibitors for 10 
minutes, followed by the addition of 10nM [3H]-dopamine for a further five 
minutes.  The range of concentrations of inhibitors or substrates employed was 
as follows: cocaine, 1 nM - 100 µM; WIN35,428, 1 nM - 10 µM; 8-oxa-
norcocaine, 1 nM - 1 mM; 4-ARA-127, 10 nM - 100 µM; mazindol, 3 nM - 10 µM; 
methylphenidate, 3 nM - 10 µM; benztropine, 0.1 nM - 30 µM; 3β-4'-
chlorobenztropine, 1 nM - 30 µM; 4'-chlorobenztropine, 0.1 nM - 30 µM; 4',4"-
difluorobenztropine, 0.1 nM - 10 µM; GBR-12,909, 0.1 nM - 10 µM; rimcazole, 1 
nM - 30 µM; N-formyl-4,4'-difluorobenztropine, 10 nM - 1 mM; and 4-
trifluoromethylbenztropine, 1 nM - 30 µM.  Uptake was quenched by aspirating 
the inhibitor/ radioligand solution and washing the monolayer with 2 x 1 ml of 
KRH containing ascorbic acid (KRH/AA).  Nonspecific binding was assessed with 
10µM mazindol, or with 30 µM cocaine if the drug tested was mazindol.  The 
cells in each well were then lysed with 1 mL of 1% SDS and incubated at room 
temperature for 1 hour with gentle shaking.  The lysate was transferred into 
scintillation vials containing 5 mL ScintSafe fluid and radioactivity was counted 
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using a liquid scintillation counter.  Ki values for [3H]dopamine uptake inhibition 
were determined with GraphPad Prism 3.0. 
 
7.  [3H]WIN35,428 saturation binding assays 
All binding assays were conducted with stable DAT-CHO cells or transient 
DAT-COS 7 cells subcultured in six-well plates.  [3H]WIN35,428 was the 
radioligand used in all binding assays.  This compound is structurally similar to 
cocaine, labels both the high- and low- affinity binding sites just as cocaine, but is 
more stable in vitro.   For [3H]WIN35,428 saturation binding assays, serial 
dilutions of WIN35,428 (1 nM - 10 µM) were made in KRH/AA buffer.  
[3H]WIN35,428 was added to each dilution of drug to achieve a final 
concentration of approximately 1 nM for the radioligand.  Cell monolayers in 6-
well plates were then washed with 2 x 1mL of KRH/AA buffer and incubated with 
the mixture of [3H]WIN35,428 and WIN35,428 for 15 minutes.  The drug solution 
was removed and the cell monolayers were washed with 2 x 1 mL KRH.  Cells 
were lysed with 1% SDS solution and the 3H content of the cell lysates was 
determined in a scintillation counter.  Bmax and Kd values for [3H]WIN35,428 
binding were determined with GraphPad Prism 3.0 software. 
 
8.  [3H]WIN35,428 binding inhibition assays 
All competition binding assays were conducted exactly as described for 
the dopamine uptake inhibition assays except that [3H]-dopamine was replaced 
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with 1nM [3H]WIN35,428 and cells were incubated with a mixture of radioligand 
and nonradioligand competitor for 15min. Briefly, serial dilutions of the drugs to 
be examined were made in KRH/AA buffer.  [3H]WIN35,428 was added to each 
dilution of drug to achieve a final concentration of 1 nM for the radioligand.  The 
range of concentrations of drugs employed were as  indicated above for 
dopamine uptake inhibition: cocaine, 1 nM - 100 µM; WIN35,428, 1 nM - 10 µM; 
8-oxa-norcocaine, 1 nM - 1 mM; 4-ARA-127, 10 nM - 100 µM; mazindol, 3 nM - 
10 µM; methylphenidate, 3 nM - 10 µM; benztropine, 0.1 nM - 30 µM; 3β-4'-
chlorobenztropine, 1 nM - 30 µM; 4'-chlorobenztropine, 0.1 nM - 30 µM; 4',4"-
difluorobenztropine, 0.1 nM - 10 µM; GBR-12,909, 0.1 nM - 10 µM; rimcazole, 1 
nM -30 µM; N-formyl-4,4'-difluorobenztropine, 10 nM - 1 mM; and 4-
trifluoromethylbenztropine, 1 nM - 30 µM).  To begin with, cell monolayers in 6-
well plates were washed with 2 x 1mL of KRH/AA buffer and incubated with the 
mixture of radioligand and nonradioactive competitor for 15 minutes.  The 
experiment was quenched by aspirating the test solution and washing the cell 
monolayers twice (2 x 1 mL) with KRH/AA buffer.  Nonspecific binding was 
assessed by addition of 10µM mazindol except when mazindol was the drug 
tested, in which case 30µM cocaine was substituted.  The cell monolayers were 
then lysed with 1 mL of 1% SDS solution and incubated at room temperature for 
1 hour with gentle shaking.  Cell solution from each well was then transferred to 
scintillation vials containing 5 mL of ScintSafe fluid and radioactivity was counted 
using a scintillation counter.  Ki, Kd, and BMAX values were determined with 
GraphPad Prism 3.0 software. 
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9.  Protein assays 
 Stable DAT-CHO cells or transient DAT-COS 7 cells subcultured in 6-well 
plates were used for protein assays.  For every experiment carried out that 
required estimates of protein content, two wells were reserved for this purpose.  
The confluent cell monolayers in 6-well plates were washed with 2 x 1 mL PBS.  
Cells in each well were then lysed with 0.5 mL of 0.2N NaOH solution, scraped 
with a rubber policeman, and incubated for 30 min at 4oC with gentle shaking.  
The cell lysates were transferred into Eppendorf tubes for storage at -20oC or for 
immediate estimation of protein content.  Protein assays were conducted 
according to the method of Bradford.  For each assay, carried out in duplicate, 
780 µL of water was added to 20 µL of cell lysate in a test tube and mixed gently.  
200 µL of BioRad “micro-Bradford” reagent was then added to the cell solution, 
vortexed for 10 sec, and incubated at room temperature for 5 min.  The 
absorbance of the protein/ dye solution was measured at 595 nm using a 
spectrophotometer.  The concentration of protein was calculated by interpolating 
the absorbance reading of the sample protein using protein standard curve. 
This curve was generated using BSA (1mg/mL stock solution) as protein 
standard.  A serial dilution of the BSA stock solution in water was performed to 
make six different concentrations of BSA such that the final concentrations were 
1, 2, 3, 4, 5, and 6 µg/ mL.  The initial volume for each dilution was 800 mL (e.g. 
for 2µg/ mL: 2µL of 1mg/mL BSA + 798 µl of water).  200 µL of BioRad reagent 
was then added to each test tube containing the protein dilutions (bringing the 
total volume of reaction to 1 mL), vortexed for 10 sec, and incubated at room 
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temperature for 5 min.  The absorbance of each protein dilution was read at 595 
nm using a spectrophotometer.  A protein standard curve (plot of absorbance 
versus amount of protein) was generated using the Excel software. 
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III.  RESULTS AND DISCUSSION 
 
A.  Results 
1.  Expression, localization and function of WT DAT and D79 mutant DATs 
 WT DAT and four D79 mutant DATs (D79A, D79E, D79L, D79N) were 
screened for their abilities to bind [3H]WIN35,428, take up [3H]dopamine, or 
target to the cell membrane.  The mutant DATs were made by site-directed 
mutagenesis and confirmed by DNA sequencing.  These mutants were used to 
characterize features of the TM1 aspartic acid residue important for dopamine 
uptake and inhibitor recognition.  A mutation from aspartate to alanine (D79A) 
results in a large decrease in size and a loss of charge and polarity of the 
residue.  The mutation of aspartate 79 in rDAT to glutamate (D79E) is a 
conservative exchange as these two amino acids differ from one another only by 
one methylene group.  The D79L mutation provides a leucine side chain that 
causes a loss in the negative charge and hydrogen bonding potential of 
aspartate but retains a size similar to that of aspartate.  An asparagine for 
aspartate substitution at position 79 of DAT (D79N) eliminates the negative 
charge but retains the hydrogen bonding potential of the residue.  All constructs 
were assessed in parallel using a one point binding assay.  Relative to WT DAT, 
only the D79E DAT mutant displayed detectable specific binding of 
[3H]WIN35,428 (P<0.05, compared with vector transfected cells) (Fig. 3).   
The D79 mutant DATs were also tested for functional uptake by incubating 
COS 7 cells transiently transfected with the cDNA of WT DAT or the D79 mutant 
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DATs with 10 nM [3H]dopamine for 5 min at 22oC.  The D79E DAT mutant was 
yet again the only mutant DAT that displayed functional uptake of [3H]dopamine 
(P<0.001, compared with vector-transfected cells) (Fig. 4).   
 
 
 
              
 
Figure 3.  Determination of [3H]-WIN35,428 specific binding by COS-7 cells expressing WT 
or D79 mutant DAT proteins.  
The extent of specific [3H]-WIN35,428 binding as a percentage of WT DAT was assessed 
for cells transiently transfected with plasmids encoding D79A, D79E, D79L or D79N DAT, or the 
plasmid vector lacking DAT sequence (“Vec”). The data represent an average of 5 separate 
experiments. * P < 0.05 (Student T test) relative to "vector alone" control.  Reprinted with 
permission from ASPET from Ukairo et al., 2005. 
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Figure 4.  Determination of [3H]-dopamine uptake ability by COS-7 cells expressing WT or 
D79 mutant DAT proteins.  
The extent of total [3H]-dopamine uptake as a percentage of WT DAT was assessed for 
cells transiently transfected with plasmids encoding D79A, D79E, D79L or D79N DAT, or the 
plasmid vector lacking DAT sequence (“Vec”). The data represent an average of 5 separate 
experiments. *P< 0.001 (Student T test) relative to "vector alone" control. 
 
Confocal microscopy experiments, however, showed that all the DAT 
protein constructs tested were expressed at the cell surface (Fig. 5).  Cell surface 
expression of WT DAT and D79 mutant DAT proteins had earlier been confirmed 
by biotinylation and western blotting data from our laboratory; D79N DAT, 
nevertheless, displayed a diminished cell surface expression when compared to 
WT DAT (Wang et al., 2003).  The fact that all D79 mutant DATs were expressed 
on the cell plasma membrane suggests that the functional and radioligand 
binding deficits observed were not due to an inability to target to the cell surface. 
Only the WT DAT and D79E DAT mutant were further characterized due to the 
failure to detect either radioligand specific binding (Fig. 3) or [3H]-dopamine 
uptake (Fig. 4) in the other mutant constructs.  
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Figure 5.  Localization of WT or D79 mutant DAT in DAT-COS 7 cells under confocal laser-
scanning microscope.  
COS 7 cells transiently transfected with WT DAT or D79 mutant DAT were stained with 
monoclonal anti-DAT antibody and visualized with Alexa Fluor 488 (green signal). The cells were 
also stained with rhodamine phalloidin (red signal) to label cortical F-actin, a marker at the cell 
membrane. Overlay view (yellow signal) shows the co-localization of WT DAT or D79 mutant DAT 
with F-actin. Shown are representative confocal images of four different experiments. Scale bar = 
8.00µm for all images.  Reprinted with permission from ASPET from Ukairo et al., 2005. 
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2.  Assessing the role of DAT TM 1 D79 residue in dopamine uptake 
 The dopamine uptake inhibition potencies (DUIPs) and binding affinities 
of various dopamine analogs at WT DAT and D79E DAT were tested.  This study 
investigated the effect of modifying the catechol moiety of dopamine to overall 
substrate transport and also verified whether the D79 side chain of DAT was 
involved in recognition of some feature of the substrate catechol ring moiety.  
The drugs tested were: (+)-amphetamine, (-)-amphetamine, p-tyramine, m-
tyramine, norepinephrine, and dopamine (Fig. 6).   
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Figure 6.  Chemical structures of DAT substrates employed in [3H]-WIN35,428 and [3H]-
dopamine displacement assays. 
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The Km for dopamine uptake and the Ki for dopamine inhibition of 
[3H]WIN35,428 binding were unaffected by the D79E mutation (Table 1).  These 
data contradict the long-held hypothesis of an ionic interaction between 
dopamine and aspartate-79 as being the principal means of interaction between 
dopamine and the DAT.   Norepinephrine (addition of a β-OH group to dopamine) 
was equipotent at both WT DAT and D79E DAT at inhibiting dopamine uptake.  
On the other hand, the D79E mutation caused a two-fold loss in the binding 
affinity of norepinephrine (Table 1).  The D79E mutation had little or no effect on 
the DUIPs of m-tyramine or p-tyramine (each lacking one of the catechol OH 
groups found in dopamine); the mutation, nevertheless, decreased the binding 
affinities of both compounds by more than 5-fold (Fig 7, and Table 1).  The D79E 
mutation induced a 5-fold loss in the DUIP and a 9-fold loss in the binding affinity 
of S(+)-amphetamine (lacking both catechol OH groups and adding an α–methyl 
group) (Table 1).  The DUIP of the less psychoactive R(-)-amphetamine isomer 
was not significantly affected by the D79E mutation, but its binding affinity was 
diminished by about 4-fold (Table 1).  The DUIPs for m-tyramine, p-tyramine and 
(-)-amphetamine at both DAT constructs suggest that loss of one or both 
catechol OH groups was tolerated by D79E DAT, while the binding affinities of 
the three substrates were markedly diminished by the mutation. 
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Figure 7.  m-Tyramine or p-Tyramine inhibition of [3H]-dopamine uptake or [3H]WIN35,428 
binding. 
The [3H]-dopamine uptake inhibiton (A and C) and inhibition of [3H]WIN35,428 binding (B 
and D) experiments were done under identical conditions at CHO cells stably transfected with WT 
DAT (filled symbols) or D79E DAT (open symbols).  The data are representative of at least three 
independent experiments. 
 
 
 
 
 
  
 59
Table 1.  Effect of DAT substrates on CHO cells stably expressing WT and D79E DAT.   
KM and Ki values were derived from experiments incubating the stably transfected cells 
with nonradioactive substrates in the presence of [3H]-dopamine or [3H]-WIN35,428 at 22OC in 
KRH/AA buffer.  Values are presented as mean ± S.E.M. for three to six independent 
experiments.  Reprinted with permission from ASPET from Wang, Sonders, Ukairo et al., 2003. 
 
  Ki or KM  
WT DAT  D79E DAT 
  (µM)  
[3H]- dopamine uptake    
Dopamine 1.7 ± 0.3  2.3 ± 0.3 
Norepinephrine 5.4 ± 0.5a  5.2 ± 0.3a
m-Tyramine 1.4 ± 0.3  1.2 ± 0.3a
p-Tyramine 1.7 ± 0.1  3.3 ± 0.4b
(+)-Amphetamine 0.5 ± 0.1  2.4 ± 0.3b
(-)-Amphetamine 2.8 ± 0.5  4.2 ± 0.5a
[3H]-WIN35,428 inhibition    
Dopamine 2.1 ± 0.2  2.5 ± 0.4 
Norepinephrine 2.3 ± 0.5c  5.5 ± 0.7a,b
m-Tyramine 1.0 ± 0.2a  6.6 ± 1.2a,b,c
p-Tyramine 0.8 ± 0.1a,c  4.3 ± 0.5b
(+)-Amphetamine 0.4 ± 0.1a  3.7 ± 0.8b
(-)-Amphetamine 2.0 ± 0.2  8.1 ± 0.5a,b,c
 
 
a P<0.05 versus dopamine for the given assay and DAT construct (Student’s T test) 
b P<0.05 versus WT DAT for that assay (Student’s T test) 
c P<0.05 for [3H] for WIN inhibition versus dopamine uptake at the same DAT construct (Student’s 
T test) 
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3.  Effect of DAT inhibitors on CHO cells stably expressing WT or D79E 
DAT 
WT DAT and D79E DAT stably-transfected CHO-K1 cell lines were 
employed to characterize the DUIPs and binding affinities of various DAT 
inhibitors (Fig 8).  In order to better assess the key functional groups important 
for DAT recognition, DAT inhibitors containing various pharmacophore 
modifications of cocaine were selected for analysis.  The Ki values for DUIP and 
binding affinity were obtained from inhibition of [3H]-dopamine uptake and [3H]-
WIN35,428 binding inhibition experiments respectively; both assays were carried 
out under the same conditions.  Previously, it was shown that the D79E DAT 
mutation had little or no effect on the DUIPs of the classical DAT inhibitors 
cocaine, WIN35,428, methylphenidate and mazindol (Wang et al., 2003).  Except 
for benztropine (structurally different from cocaine by having a diphenylmethoxy 
group at the C-3 position), all other drugs studied here displayed this same DUIP 
pattern.  The DUIP of 8-oxa-norcocaine, an analog of cocaine lacking the tropane 
nitrogen and thus a positive charge, was unaffected by the D79E mutation (Table 
2).  Furthermore, the DUIPs of 4-ARA-127, rimcazole and GBR-12909 (all 
compounds containing the piperidine or piperazine substitution of the tropane 
ring) were unaffected by the D79E DAT mutation (Fig. 9, and Table 2).  In 
contrast, the DUIP of benztropine was 8 fold higher at D79E DAT than at WT 
DAT, a deviation from the trend observed for the other drugs (Fig 9 and Table 2).   
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Figure 8.  Chemical structures of DAT inhibitors employed in [3H]-WIN35,428 and [3H]-
dopamine displacement assays.   
Reprinted with permission from ASPET from Ukairo et al., 2005. 
 
  
 62
The mutation had a different effect on the binding affinities of the drugs studied.  
The binding affinities of cocaine, WIN35,428, 8-oxa norcocaine, mazindol, and 
methylphenidate were about 3-8 fold less at D79E DAT when compared with WT 
DAT values.  The mutation had no effect on the binding affinities of GBR-12,909 
and rimcazole but elevated the binding affinity of ARA-127 by 2-fold (Table 2).  
As was earlier reported for cocaine, WIN35,428, methylphenidate, and mazindol, 
the binding affinities for rimcazole and 8-oxanorcocaine were 3-6 fold higher than 
their DUIPs at WT DAT.  The binding affinities for 4-ARA-127 and GBR-12,909 at 
WT DAT were 2 fold lower than their DUIPs (Table 2).  On the other hand, 
benztropine was equipotent at inhibiting [3H]WIN35,428 binding and 
[3H]dopamine uptake at WT DAT (Tables 2 and 3).  The binding affinities and 
DUIPs of cocaine, mazindol, methylphenidate, WIN35,428, and 4-ARA-127 at 
D79E DAT were identical (Table 2).  For 8-oxa-norcocaine and rimcazole, 
however, the binding affinity at D79E DAT was 2 - 4 fold higher than DUIP.  
Benztropine and GBR-12,909 were 3 fold less potent as inhibitors of 
[3H]WIN35,428 binding than as inhibitors of [3H]dopamine uptake at D79E DAT 
(Tables 2 and 3).  
Seeing that the D79E mutation affected only the DUIP of benztropine, the 
pharmacological profiles of structural analogs of this drug were further examined 
at WT and D79E DAT.  Except for 4',4"-difluoroBZT and GBR-12,909, the DUIPs 
of all other benztropine analogs were diminished by the D79E mutation but to 
different extents (Table 3).  Intriguingly, the considerably different DUIPs of the  
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Figure 9.  Effect of DAT inhibitors on CHO cells stably expressing WT or D79E DAT 
GBR-12,909 (squares), methylphenidate (diamonds) and benztropine (circles) inhibition 
of [3H]-dopamine uptake (left graph) or [3H]-WIN 35,428 binding (right graph) under identical 
conditions at CHO cells stably transfected with WT DAT (filled symbols) or D79E DAT (open 
symbols). The data are representative of at least 3 independent experiments.  Reprinted with 
permission from ASPET from Ukairo et al., 2005. 
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Figure 10.  Effect of benztropine and BZT analogs on CHO cells stably expressing WT or 
D79E DAT.   
Benztropine (circles), 4'-chlorobenztropine (upright triangles) and 3β-4'-chlorobenztropine 
(inverted triangles) inhibition of [3H]-dopamine uptake (left graph) or [3H]-WIN 35,428 binding 
(right graph) under identical conditions at CHO cells stably transfected with WT (filled symbols) or 
D79E DAT (open symbols). The data are representative of at least 3 independent experiments.  
Reprinted with permission from ASPET from Ukairo et al., 2005. 
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benztropine analogs (ranging from 15 – 964 nM) at the WT DAT were unified to 
approximately 20 nM at D79E DAT (Fig. 10 and Table 3).  Additional benztropine 
analogs were investigated to assess the effects of adding larger groups to the 
tropane and phenyl rings.  Replacement of the N-methyl group of 4',4"-
difluoroBZT with the charge-neutral N-formyl group (N-CHO-4,4’-diFBZT) caused 
a profound reduction in DUIPs at both WT and D79E DAT (Table 3).  Although 
the D79E mutation increased the DUIP of this compound, the Ki for inhibiting 
dopamine uptake diverged from the Ki of 20 nM at D79E DAT observed for other 
benztropine analogs.  The binding affinity of N-CHO-4,4’-diFBZT was increased 
by 3 fold by the mutation.  4'-trifluoromethylBZT, a benztropine analog having a 
larger aryl group on one of the phenyl rings, also diverged from the 20 nM DUIP 
D79E DAT pattern. The D79E mutation increased the DUIP of 4'-
trifluoromethylBZT by about 4 fold but had no effect on its binding affinity (Table 
3).  Interestingly, the 3β-4-chlorobenztropine compound (with its diphenyl ether 
group in the β position) also yielded a DUIP of approximately 20 nM at D79E 
DAT. The mutation caused a 37-fold increase in the DUIP of 3β-4-
chlorobenztropine in order to achieve the 20 nM DUIP. 
For most of the benztropine analogs, the D79E mutation had no effect on 
their binding affinities.  Increased binding affinities due to the mutation were 
observed only for 3β-4-chloroBZT (3 fold) and N-formyl-difluoroBZT (5-fold) 
(Table 3).  The DUIP data of benztropine and its analogs suggested a connection 
between modifications of the tropane ring C-3 position of cocaine and 
modifications of the DAT D79 side chain.  
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Table 2.  Dopamine uptake inhibition potencies and binding affinities of structurally 
diverse DAT inhibitors at CHO cells stably expressing WT or D79E DAT.   
Kd (WIN35,428 only) and Ki values were derived from experiments incubating the stably-
transfected cells with nonradioactive ligands in the presence of [3H]dopamine or [3H]WIN35,428 
at 22oC in KRH/AA buffer.  Values are presented as Mean ± SEM for 3 - 6 independent 
experiments.  Of the 9 structurally diverse DAT blockers studied, only the DUIP of benztropine 
was substantially altered by the D79E mutation.  Reprinted with permission from ASPET from 
Ukairo et al., 2005. 
 
 
   Ki (nM)  
 WT  D79E 
[3H]- Dopamine uptake    
WIN35,428a 74 ± 17  71 ± 12 
ARA-127 1630 ± 200  1540 ± 120 
Cocainea 555 ± 29  1126 ± 32b
Oxa-norcocaine 9777 ± 1489  8196 ± 340 
Mazindola 31 ± 3  47 ± 4 
Methylphenidatea 152 ± 20  161 ± 9 
Benztropine 160 ± 37  19 ± 3b
GBR-12,909 15 ± 3  40 ± 9 
Rimcazole 643 ± 43  691 ± 76 
[3H]-WIN35,428 inhibition    
WIN35,428a 20 ± 1c  68 ± 4b
ARA-127 3300 ± 40c  1570 ± 210b
Cocainea 128 ± 5c  1066 ± 84b
Oxa-norcocaine 1564 ± 212c  5533 ± 653b,c
Mazindola 13 ± 1c  41 ± 3b
Methylphenidatea 57 ± 3c  167 ± 2b
Benztropine 127 ± 22  51 ± 5b,c
GBR-12,909 31 ± 5  40 ± 9 
Rimcazole 180 ± 26c  226 ± 38c
 
 
 
a Wang et al. (2003) Mol. Pharmacol. 64: 430 - 439   
b P<0.05 versus WT DAT for that assay 
c P<0.05 for WIN inhibition vs. dopamine uptake at the same DAT construct 
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Table 3.  Dopamine uptake inhibition potencies and binding affinities of benztropine and 
its analogs at CHO cells stably expressing WT or D79E DAT.   
Ki values were derived from experiments incubating the stably-transfected cells with 
nonradioactive inhibitors in the presence of [3H]dopamine or [3H]WIN35,428 at 22oC in KRH/AA 
buffer.  Values are presented as mean ± SEM for 3 - 6 independent experiments.  Reprinted with 
permission from ASPET from Ukairo et al., 2005.  
  
 
  Ki (nM)  
 WT DAT  D79E DAT 
[3H] - Dopamine uptake    
Benztropine 160 ± 37  19 ± 3a
4-chloroBZT 83 ± 6  19 ± 3a
3β-4-chloroBZT 964 ± 161  26 ± 4a
4,4'-difluoroBZT 22 ± 4  18 ± 3 
4-trifluoromethylBZT 1282 ± 79  330 ± 36a
N-CHO-4,4’-diFBZT 21760 ± 2857  1575 ± 452a
GBR-12,909 15 ± 3  14 ± 3 
[3H]–WIN35,428 inhibition    
Benztropine 127 ± 22  51 ± 5a,b
4-chloroBZT 45 ± 6b  44 ± 10b
3β-4-chloroBZT 680 ± 123  120 ± 35a,b
4,4'-difluoroBZT 8 ± 1b  9 ± 2b
4-trifluoromethylBZT 541 ± 71  359 ± 25 
N-CHO-4,4’-diFBZT 12730 ± 1996  3840 ± 746a
GBR-12,909 31 ± 5  40 ± 9 
 
 
 
aP<0.05 versus WT DAT for that assay 
bP<0.05 for WIN inhibition vs. dopamine uptake at the same DAT construct 
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4.  Effects of cell age, density and DAT cell surface expression on the 
DUIPs of classical DAT inhibitors 
Previous observations indicated that the DUIP of cocaine at WT DAT 
varied with cell age (C.K. Surratt, unpublished data).  The study was enlarged to 
determine whether this phenomenon was unique to cocaine or could be 
extended to other classical DAT inhibitors such as mazindol, methylphenidate, 
and benztropine.  The influence of cell density (%confluence) and DAT cell 
surface expression levels on inhibitor DUIP fluctuation was also investigated.  
The WT DAT-CHO K1 stable cell line was used for the study.  Cells in passages 
9 - 20, 25 - 36, and 40 - 54 were described as “low”, “medium”, and “high” 
passage cells, respectively.  The DUIPs for these classical DAT blockers differed 
between “low passage” (P9 - P20) and “high passage” (P40 - P54) WT DAT CHO 
cells in a statistically significant fashion (Fig 11 and Table 4).  The Ki value for 
inhibition of [3H]dopamine uptake (for all the drugs tested) was about 2 fold less 
at low passages when compared with high passage values.  In contrast, assays 
conducted in parallel indicated that apparent binding affinities (measured by 
displacement of [3H]-WIN35,428) of these 4 inhibitors were not subject to cell 
passage number.  WT DAT Bmax values for [3H]-WIN35,428 binding varied 
significantly between the “low” and “high” passage cells; however, the Kd values 
for all treatment groups remained unchanged (Table 4).   
The DUIP of cocaine at WT DAT-CHO cells grown to different densities in 
6-well plates was also investigated.  Neither the DUIP nor the apparent binding 
affinity of cocaine was influenced by the density (% confluence) of the cell 
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monolayer (Table 5).  The cells were grown to 20%, 100% and 150% confluence.  
The monolayer is defined as “100% confluent” when all cells appeared to be in 
contact with neighboring cells, so as not to leave open spaces on the culture 
dish.  
Manipulation of WT DAT expression level via transient transfection of 
COS-7 cells with an amount of DAT plasmid cDNA 4-fold lower than optimal 
resulted in a statistically significant fluctuation in the dopamine uptake inhibition 
potency of cocaine (Table 6). 
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Figure 11.  Effect of methylphenidate on WT DAT-CHO cells of different passage numbers. 
Methylphenidate inhibition of [3H]-dopamine uptake (left panel) or [3H]-WIN35,428 binding 
(right panel) under identical conditions at WT DAT CHO cells of different passage number.  The 
data are representative of at least 3 independent experiments.  Passages of 9 -20, 25 - 36 and 40 
- 54 were classified as “low”, “medium” and “high”, respectively. 
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Table 4.  Effect of DAT blockers on WT DAT-CHO cells of different passage numbers. 
Inhibition of [3H]-dopamine uptake or [3H]-WIN35,428 binding by classical DAT blockers 
under identical conditions at WT DAT CHO cells of different passage number.  Ki values were 
derived from experiments incubating the stably-transfected cells with nonradioactive DAT 
inhibitors in the presence of [3H]-dopamine or [3H]-WIN 35,428 at 22OC in KRH buffer.  Passages 
of 9 -20, 25 - 36 and 40 - 54 were classified as “low”, “medium” and “high”, respectively.  (The 
ranges for an individual drug were narrower, as testing with a given inhibitor was completed 
before the next inhibitor was addressed).  Mean ± SEM for at least 3 independent experiments. 
 
 
 Cell Passage 
 Low Medium High 
  Ki (nM)  
[3H]-DA uptake inhibition    
Cocaine 719 ± 94 1055 ± 52 1503 ± 127a
Mazindol 44 ± 4 74 ± 5 93 ± 17a
Methylphenidate 352 ± 17 640 ± 22 662 ± 45a
Benztropine 236 ± 40 395 ± 45 413 ± 27a
[3H]-WIN35,428 inhibition    
Cocaine 179 ± 22 197 ± 22 251 ± 28 
Mazindol 15 ± 2 19 ± 2 20 ± 2 
Methylphenidate 74 ± 7 72 ± 5 85 ± 6 
Benztropine 78 ± 6 85 ± 9 92 ± 10 
[3H]-WIN35,428 binding     
Kd (nM) 17 ± 1 17 ± 2 18 ± 1 
Bmax (pmol/mg) 9 ± 2 11 ± 2 19 ± 3b
 
 
 
aP < 0.05 vs. low passages for the same drug in the uptake assay (one-way ANOVA, Newman-
Keuls post hoc test) 
bP < 0.05 vs. low passages in the [3H]WIN35,428 saturation binding assay (one-way ANOVA, 
Newman- Keuls post hoc test). 
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Table 5.  Effect of cell density on the DUIP and binding affinity of cocaine at WT DAT-CHO 
cells. 
Cocaine inhibition of [3H]-dopamine uptake or [3H]-WIN35,428 binding under identical 
conditions at WT DAT CHO cells as a function of cell density (% confluence).  Experiments were 
carried out with intact cell monolayers at 20%, 100%, and 150% confluence.  Ki values were 
derived from experiments incubating the stably-transfected cells with cocaine in the presence of 
[3H]-dopamine or [3H]-WIN35,428 at room temperature in KRH buffer. Data are mean ± SEM for 3 
- 4 experiments.  
 
 
      Confluence (Cell Density) 
 20% 100% 150% 
    
 Ki (nM) 
Cocaine    
[3H]-DA uptake inhibition 505 ± 108 534 ± 109 540 ± 62 
[3H]-WIN35,428 inhibition 260 ± 25 240 ± 12 201 ± 16 
 
 
 
Kinetic analysis of [3H]dopamine uptake revealed a significant increase 
(P<0.05, one-way ANOVA; n = 4) in Vmax of dopamine uptake in WT DAT-CHO 
cells with increasing cell passage number (low<medium<high) (Fig 12 and Table 
7).  This increase in Vmax was associated with an increase in WT-DAT cell 
surface expression (Bmax) at higher passage numbers.  The turnover number of 
WT DAT (expressed as Vmax/Bmax), however, did not vary significantly between 
the “low”, “medium” and “high” passage cells (Table 7).  A statistical comparison 
of the Vmax/Bmax values for the different groups was not possible as these are 
ratios of mean values.  “Low”, “medium” and “high” passage cells showed no 
significant changes in Km values for [3H]dopamine uptake. 
 
  
 71
Table 6.  Effects of DAT cell surface expression on the DUIP of cocaine  
Cocaine inhibition of [3H]-dopamine uptake by COS-7 cells transiently transfected with 
various amounts of a plasmid cDNA encoding WT DAT.  “PolyFect”-mediated transient 
transfections were carried out using 375, 750 or 1500 ng WT DAT - pIRES plasmid per 35 mm 
well containing a confluent monolayer of COS-7 cells.  Cell monolayers were assayed for [3H]-
dopamine uptake and its inhibition by cocaine at room temperature in KRH buffer 48 hours after 
transfection.  Ki values are the Mean ± SEM for 3 experiments. 
 
 
 WT DAT – pIRES Plasmid 
 ng DNA / 35 mm well 
 375 750 1500 
  Ki (nM)  
[3H]-DA uptake inhibition  
Cocaine 228 ± 7 353 ± 20 558 ± 75a
[3H]-WIN35,428 binding    
Kd (nM) 12 ± 2 15 ± 2 14 ± 2 
Bmax (pmol/mg) 0.8 ± 0.4 2.0 ± 0.5 4.0 ± 0.2 
 
 
aP < 0.05 vs. dopamine uptake inhibition Ki values for assays employing 375 ng plasmid 
transfections (one-way ANOVA, Newman-Keuls post hoc test) 
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Figure 12.  Dopamine uptake saturation kinetics of WT DAT CHO cells of different passage 
numbers.   
CHO cells stably transfected with WT DAT were incubated with increasing concentrations 
of a fixed ratio of [3H]dopamine: nonradioactive dopamine (0.5 – 16 µM dopamine at 0.1 Ci/mmol) 
as indicated in the method section.  The data are representative of 4 independent experiments.  
Passages of 9 -20, 25 - 36 and 40 - 54 were classified as “low”, “medium” and “high”, 
respectively.  Km and Vmax values were determined by fitting the rate versus concentration data.  
The inset shows an Eadie- Hofstee plot of the data with lines drawn from the derived kinetic 
constants.  See Table 7 for a summary of the calculated data. 
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Table 7.  Kinetic and binding characteristics of rDAT wild-type in CHO cells of different 
passage numbers.   
Km and Vmax values were derived from uptake experiments incubating the WT DAT cells 
with dopamine at 0.1 Ci/mmol for 5 min at 22oC.  Nonlinear regression analysis was employed to 
accurately determine Km and Vmax values.  Bmax values were derived from [3H]WIN35,428 
saturation binding experiments.  Km, Vmax, and Bmax values are the mean ± SEM for at least three 
independent experiments. 
 
 
 Cell Passage 
 Low Medium High 
Vmax(pmol/min.mg protein-1) 681 ± 18 1136 ± 85a,b 1645 ± 202a
Km (µM) 1.1 ± 0.2 1.4 ± 0.2 2.0 ± 0.4 
Bmax (pmol/mg) 9 ± 2 11 ± 2 19 ± 3c
Vmax/Bmax 76/min 103/min 87/min 
 
 
 
aP < 0.05 vs. low passages in the uptake assay (one-way ANOVA, Newman-Keuls post hoc test) 
bP < 0.05 vs. high passages in the uptake assay (one-way ANOVA, Newman-Keuls post hoc test) 
cP < 0.05 vs. low passages in the [3H]WIN35,428 saturation binding assay (one-way ANOVA, 
Newman- Keuls post hoc test). 
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B.  Discussion 
A TM 1 aspartic acid residue (Position 79 in the DAT) is conserved among the 
NSS proteins that conduct the aromatic monoamine neurotransmitters dopamine, 
norepinephrine, epinephrine and serotonin across the plasma membrane.  This 
negative charge on aspartic acid has been proposed to serve as the counter-ion 
for the positively charged nitrogen atom present in all classical DAT inhibitors 
including cocaine (Carroll et al., 1992).  In the present study alanine, leucine, 
asparagine or glutamate substitutions at this position were generated in order to 
assess the importance of side chain length, hydrogen bonding potential and 
negative charge for recognition of DAT inhibitors.  Only the D79E DAT mutant 
displayed detectable specific binding of [3H]-WIN35,428 (Fig. 1) or functional 
uptake of [3H]dopamine (Fig. 2).  Consequently, only WT DAT and D79E DAT 
stably transfected cell lines were employed in the present study with a range of 
DAT substrates as well as DAT blockers either structurally dissimilar to cocaine 
or containing variations of the 3 primary components of the cocaine 
pharmacophore, the positively charged tropane nitrogen atom, the tropane ring, 
and the C-3 aromatic substituent. 
 Using various dopamine analogs, the possibility that D79 is involved in 
recognition of some feature of the substrate catechol ring moiety was tested.  
The dopamine uptake inhibition potencies for the tyramines and (-)-amphetamine 
at WT versus D79E DAT indicated, however, that loss of one or both catechol 
hydroxyl groups were essentially tolerated by D79E DAT.  Binding affinities for 
these three substrates, on the other hand, were reduced several fold by the 
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mutation.  The result suggests that different DAT conformations or populations 
are responsible for DUIP and high affinity binding.  Thus, one DAT conformation 
or population is apparently more sensitive to alterations in the substrate catechol 
moiety than is a second DAT conformation/population.  An "aromatic pocket" role 
for the DAT D79 residue is consistent with the fact that the aspartate is 
conserved among the NSS proteins whose substrates bear an aromatic moiety.  
A glycine residue is found in the analogous position for members of the same 
transporter family that recognize nonaromatic substrates (eg. Glycine, GABA, 
betaine) that nevertheless retain the protonated amino group (Wang et al., 2003). 
As stated above, the aromatic moiety of dopamine would be the most logical 
substrate functional group to show dependence on the D79 DAT residue. 
To investigate the importance of the positive charge of cocaine to its 
action at the DAT, we employed a compound for which the N-8 of the tropane 
ring was replaced with a charge-neutral oxygen atom, a modification that has 
previously been shown to spare dopamine uptake inhibition potency (DUIP) and 
specific binding at WT DAT (Kozikowski et al., 1999).  The Ki for inhibition of 
dopamine uptake by 8-oxa-norcocaine at D79E DAT was similar to WT values; 
binding affinity was, however, diminished by almost 4 fold (Table 1).  The 
glutamate-for-aspartate switch is often thought of as a conservative mutation.  
Recent findings indicate that although these two amino acids differ only by one 
methylene group, they have different spatial preferences (Johnson and Peterson, 
2001).  Furthermore, aspartic acid has been shown to favor interactions between 
the side chain carbonyl group and a backbone carbonyl group resulting in a ring-
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like structure which is not observed for glutamic acid (Deane et al., 1999).  
Consequently, if D79 is actually situated in the binding pocket of the DAT, a 
D79E mutation should introduce some steric hindrance to the ligand binding 
cavity considering the different spatial preferences of the two amino acids.   The 
observation that the DUIP of this charge-neutral cocaine analog is unaltered by 
an allegedly more crowded binding pocket is not in agreement with (but not 
exclusive of) the postulate that a salt bridge between the D79 residue and the N-
8 atom is the principal, governing DAT - cocaine interaction.  The 8-oxa-
norcocaine compound paralleled cocaine in that Ki values suggest its affinity to 
be several fold greater than its DUIP at WT DAT, and in that its affinity and DUIP 
values were less than 2 fold apart at D79E DAT. 
 To verify the significance of the cocaine tropane ring with respect to the 
D79 side chain, DAT inhibitors that possess a piperidine or piperazine in place of 
the tropane ring were employed in binding and uptake inhibition assays (Table 
2).  A number of piperidine-based cocaine analogs have been shown to be 
effective in blocking binding of DAT ligands or dopamine uptake at the DAT 
(Kozikowski et al., 1998; Tamiz et al., 2000), demonstrating that the tropane ring 
of cocaine is not absolutely required for cocaine action at the transporter.  The 
compound employed in the present work, 4-ARA-127, is a WIN35,428 analog 
that lacks the 6,7-bridgehead of the tropane ring and contains a p-chlorophenyl 
instead of a p-fluorophenyl substituent on what would be C-3 of the tropane ring 
(Fig. 3).  The D79E mutation had little or no effect on the pharmacology of this 
piperidine-based cocaine analog (Table 2).  The D79E mutation also did not alter 
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the pharmacological profile of the piperazine-based compounds, GBR-12,909 
and rimcazole (Table 2).  These data indicate that the role of the D79 residue 
may not include recognition of the tropane ring (or piperidine/piperazine ring 
replacement) of these DAT inhibitors. 
It was predicted that the third position of the cocaine pharmacophore, an 
aromatic group at the tropane C-3 position, would be the most sensitive to 
alterations of the DAT D79 side chain.  For an inhibitor that directly blocks 
dopamine binding at a DAT site in which the D79 residue is crucial, an aromatic 
ring would be the more logical primary pharmacophore for this role.  An aromatic 
moiety is obligatory at the tropane C-3 position of cocaine for DAT inhibition, and 
even for inhibitors missing the tropane structure an aromatic ring is necessary 
(Carroll et al., 1992, Newman and Kulkarni, 2002).  Based on this fact,  the 
contribution of the tropane C-3 substituent to DAT inhibition was investigated in 
detail by testing benztropine, possessing one of the more pronounced structural 
variations at this position, with the D79E mutant.  Of 9 structurally diverse DAT 
blockers initially studied, only the DUIP of benztropine was altered to a large 
extent by the D79E mutation (Table 2). 
It is possible that the D79E mutation influences recognition of the common 
diphenylmethoxy pharmacophore given that benztropine and several of its 
analogs yielded the same DUIP at D79E DAT despite often very different DUIPs 
at WT DAT (Table 3).  Unlike WT DAT, the D79E DAT protein was by and large 
tolerant of diphenylmethoxy ring substituents, especially surprising considering 
the marked reorientation of the diphenylmethoxy moiety in the 3β-4'-
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chlorobenztropine derivative.  Optimal binding at the DAT is achieved when the 
diphenyl ether of benztropine is in the axial or α-stereochemistry; both aryl rings 
are required and cannot be held in a rigid cyclic structure (reviewed in Newman 
and Kulkarni, 2002).  The pharmacological profile of the different benztropine 
analogs at D79E DAT suggests that the D79E substitution may have enhanced 
DAT interaction with the diphenylmethoxy moiety possibly by providing a 
"roomier" binding pocket for this pharmacophore that accommodates different 
halogen substituents and ring orientations.  Both of the phenyl rings of 
benztropine may simultaneously contribute to inhibition of D79E DAT, but likely 
not when in the same plane.  The phenyl rings of rimcazole are fused and thus 
constrained in space by a bond that creates an intervening pyrrole ring (Fig. 8).  
Comparing results (Table 2) for rimcazole to those for GBR-12,909, its closest 
structural analog in this study, suggest that the phenyl rings must be able to 
rotate freely for potent dopamine uptake inhibition at the DAT.  Furthermore, 
comparative molecular field analysis (CoMFA) of benztropines contends that the 
relative orientation of the phenyl rings is important for DAT affinity (Kline et al., 
1997, Kulkarni et al., 2004). 
There is accumulating evidence that benztropine employs a DAT binding site 
distinguishable from other DAT blockers.  Newman and colleagues have 
identified dissimilarities between benztropine and cocaine actions at the DAT via 
distinctive structure-activity relationship profiles (Newman and Kulkarni, 2002).  
Benztropine altered the accessibility of alkylation agents to wildtype DAT 
cysteine residues in a pattern distinct from the pattern generated by cocaine, 
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WIN35,428 and mazindol (Reith et al., 2001).  The latter study revealed a 
primary alkylation pattern difference at C90, a DAT extracellular loop cysteine 
residue that immediately follows TM 1.  The notion that benztropine is recognized 
by a DAT protein region encompassing the TM 1 D79 residue is supported by 
other DAT structure-function findings.  Chen and colleagues showed that the 
binding affinities for benztropine and GBR12,909, but not those of cocaine or 
WIN35,428, were Na+ dependent at W84L DAT, a mutation of a TM 1 residue 
only 5 positions away from D79 (Chen et al., 2004).   
In addition to different roles of the tropane ring nitrogen and the C-3 position 
aromatic functional groups between cocaine-like and benztropine-like 
compounds, the necessity and nature of the C-2 position substituent also differs 
between these structural classes of DAT inhibitors (Newman and Kulkarni, 2002).  
Cocaine and its analogues require a substituent in the C-2 position (e.g., a 2-
methyl ester for cocaine), a substituent not required for the benztropines to 
exhibit high affinity for DAT.  Indeed, the only 2-methyl ester substituted 
benztropine with affinity for the DAT presents this substituent in a 
stereochemistry opposite to that of cocaine (Meltzer et al., 1994).  These findings 
have been confirmed and expanded (Zou et al., 2002; Zou et al., 2003), and 
preliminary behavioral evaluation of the (+)-2-ester-substituted benztropines 
suggests that the C-2 position substituent plays a role in the behavioral profile of 
these compounds (Newman and Kulkarni, unpublished data). 
From these SAR studies and the data herein, the influence of particular 
functional groups within the C-3 pharmacophore appears to be weighted toward 
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the aromatic ring system.  In the benztropine class, the 4’,4”-difluorophenyl ether 
provides optimal binding affinity at WT DAT.  Molecular modeling of benztropine 
and its most divergent analogs with respect to WT versus D79E DAT 
pharmacology indicates that C-3 aromatic substituents that reduce DUIP at DAT 
fall outside of the optimal binding pocket (Ukairo et al., 2005).  The same is true 
for the neutral tropane N-formyl group of AHN 2-032.  Considering the significant 
DUIP increases for these compounds with the D79E mutation, it may be that the 
benztropine binding pocket is modified by the mutation to increase tolerance for 
these C-3 or tropane nitrogen modifications.  With regard to the latter, it is 
possible that the cocaine and benztropine recognition sites of DAT differ in that 
D79 contributes to recognition of the C-3 pharmacophore of cocaine, but the 
tropane nitrogen of benztropine.  Nevertheless, it should be taken into account 
that the D79E mutation-induced DUIP increase was only slightly more 
pronounced for N-formylbenztropine compared to benztropine itself (Table 2). 
 The mechanism by which the D79E mutation influences the DAT binding 
affinities of the various inhibitors tested remains uncertain.  The D79E mutation 
had little or no effect on the DUIPs of cocaine, WIN35,428, mazindol and 
methylphenidate.  Conversely, their binding affinities were reduced 3-4 fold by 
this mutation (Wang et al., 2003).  The Ki value for displacement of 
[3H]WIN35,428 binding at D79E DAT by these classical DAT inhibitors matched  
their Ki values for inhibition of [3H]dopamine uptake.  Binding Ki values for these 
drugs diverged from their DUIP Ki values at WT DAT.  It appears that the 
mutation eliminates the DAT site, conformation or population responsible for 
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higher affinity binding of these drugs, while sparing the 
site/conformation/population primarily responsible for inhibition of dopamine 
uptake (Fig. 13) (Wang et al., 2003).   
 
 
DAT Population 1                     DAT Population 2 
(Lower WIN Affinity)                           (Higher WIN Affinity)
                      
DA 
 
 
Figure 13.  Model for dopamine uptake and WIN35, 428 binding at DAT 
Two DAT populations (rectangular structures) are represented at the cell surface, within 
the plasma membrane (parallel horizontal lines).  The large majority of [3H]dopamine uptake is 
proposed to be mediated by DAT population 1; population 2 is thus under-represented with 
respect to total uptake of the dopamine radiotracer. Population 1 displays a lower affinity (~70 
nM) for [3H]WIN 35,428 (WIN, inscribed in quasi-pentagonal structure) than does population 2 
(~20 nM); Population 1 is thus underrepresented with respect to total binding of the WIN 35,428 
radiotracer.  Higher levels (e.g., >500 nM) of WIN 35,428 (or other DAT inhibitors employed in the 
study) thoroughly eliminate dopamine uptake by both DAT populations, but the uptake inhibition 
curves reflect actions principally at population 1 (the primary [3H]dopamine conduit). The D79E 
mutation eliminates DAT population 2, eliminating the higher affinity binding of DAT inhibitors but 
affording little or no effect on their dopamine uptake inhibition potencies.  Reprinted from Wang, 
Sonders, Ukairo et al., 2003. 
 
 
The 8-oxa-norcocaine data are also in conformity with this hypothesis 
(Table 2).  In the case of benztropine and structurally analogous compounds, 
binding affinities and DUIPs at WT DAT were lower than, or at best, equal to, 
DA 
 WIN 
 WIN  WIN 
 WT DAT and D79E DAT                                                   WT DAT only 
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those at D79E DAT (Table 3).  Furthermore, binding affinities and DUIPs for 
these compounds at D79E DAT were dissimilar.  For these drugs, the DAT 
site/conformation/population responsible for higher affinity inhibitor binding is 
likely to be different from that for cocaine, and may be affected differently by the 
D79E substitution.   
 The idea of separate DAT populations, as opposed to simply multiple 
binding sites or conformations, is supported by the observations that the DAT 
and other monoamine transporter proteins form functional homooligomeric 
complexes (Kilic and Rudnick, 2000; Hastrup et al., 2001; Schmid et al., 2001; 
Hastrup et al., 2003; Kocabas et al., 2003) as well as complexes with membrane 
and cytoskeletal proteins including Hic-5, PICK-1, α-synuclein and syntaxin 1A 
(Torres et al., 2001; Carneiro et al., 2002; Wersinger and Sidhu, 2003; Lee et al., 
2004).  In fact, the SNARE protein syntaxin 1A, inhibits substrate uptake via 
direct interaction with GABA, glycine, serotonin and norepinephrine transporters, 
all members of the NSS transporter family which includes the DAT (Beckman et 
al., 1998; Geerlings et al., 2000; Haase et al., 2001; Sung et al., 2003).  It has 
been shown that the GABA transporter N-terminal aspartate residues directly 
interacts with syntaxin 1A to modulate transporter function (Hansra et al., 2004).  
It is conceivable, therefore, that the D79E mutation eliminates (or augments) 
DAT populations consisting of complexes with syntaxins or other endogenous 
factors (Ramsey and DeFelice, 2002).  Some TM 1 mutations have been shown 
to alter Na+ or Cl- binding, in turn altering inhibitor affinities (Mager et al., 1996; 
Barker et al., 1999; Chen et al., 2004); possibly, the D79E mutation could 
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manipulate availability of DAT sites, conformations or populations in this way.  It 
is intriguing to consider that structural modification of a DAT inhibitor may alter its 
preference for a certain DAT population, in turn selectively affecting its behavioral 
pharmacology. 
 The lack of correlation between DAT inhibitor DUIPs and apparent binding 
affinities at the WT DAT is well-documented (Pristupa et al. 1994; Eshleman et 
al. 1999) and has yet to be satisfactorily explained.  In the course of this study 
using mammalian cell lines stably-transfected with WT DAT cDNAs, it was 
observed that the DUIP of a given inhibitor will fluctuate even though the 
apparent binding affinity of the drug does not fluctuate.  In order to investigate the 
nature of this phenomenon, three possible influences on DAT function at the 
level of the cultured cell were investigated: the age of the cell line (measured by 
cell passage number), the density of the cell monolayer (i.e., percent 
confluence), and the effect of varying DAT expression level by manipulation of 
transfection conditions.  To ensure that comparisons between DUIP and 
apparent binding affinity were legitimate for a given DAT inhibitor, [3H]-dopamine 
uptake assays, binding assays involving the cocaine analog [3H]-WIN 35,428, 
and versions of each assay that included nonradioactive competitors were 
conducted under identical conditions.  As reported above, a conservative 
glutamate-for-aspartate substitution in TM 1 of the rat DAT protein (D79E) 
decreased apparent binding affinities of several classical DAT inhibitors by 3 - 8 
fold, yet yielded little or no effect on the DUIPs of these blockers (Wang et al., 
2003).  This finding implied that at least two discrete inhibitor-binding DAT sites, 
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conformations or populations exist, and that in this CHO cell system at least, the 
DAT site/conformation/population responsible for inhibitor high affinity binding is 
less responsible for dopamine uptake.  The present findings indicate that the 
“age” of the WT DAT CHO cell line, as defined by cell passage number, appears 
to be relevant to the DUIP for the classical DAT blockers cocaine, mazindol, 
methylphenidate and benztropine.  The DUIP of cocaine was also apparently 
subject to DAT expression levels.  These results can best be explained by a 
model invoking two or more DAT populations, as opposed to two or more DAT 
binding sites or conformations within the same DAT population.  The “cell 
passage number” experiment indicated that DUIPs for all inhibitors tested 
fluctuated suggesting that DAT function is regulated by an unidentified 
intracellular agent, the actions of which are sensitive to cell state (e.g., cell age).  
Reducing DAT expression while holding cell passage number constant also 
caused cocaine DUIP to fluctuate.  Taken together, these results lead us to 
postulate that inhibitor DUIP may be a property of the ratio of “naked” or 
unmodified DAT molecules to “complexed” or posttranslationally-modified DAT 
molecules.  DAT complexes may include homooligomers or heterooligomers 
(with syntaxins or other endogenous proteins/factors capable of modulating DAT 
function).  For example, cellular aging may convert most of a “complexed” or 
posttranslationally-modified population, which is less efficient in dopamine 
transport but more efficient in binding the inhibitor, to the naked or unmodified 
DAT population that is more efficient in dopamine transport but less efficient in 
binding the inhibitor.  This hypothesis is the subject of further investigation in our 
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laboratory.  Given the fact that DAT is a phosphoprotein as well as a 
glycoprotein, the use of inhibitors of DAT phosphorylation and glycosylation will 
be employed to determine the involvement of these pathways in the observed 
changes in inhibitor DUIP due to cell passages.  In addition, the influence of DAT 
oligomerization state on the observed phenomenon will also be investigated.    
If certain DAT populations are more relevant to the mechanism(s) of 
action of cocaine, amphetamines and other psychostimulants, characterization of 
such populations may further development of novel therapeutics for these drugs 
of abuse. 
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IV. CONCLUSIONS 
 
Our results may be of significance to ongoing efforts in the development of 
anti-cocaine medications.  In addressing whether the D79 side chain contributes 
to the DAT binding sites of other portions of the cocaine pharmacophore, only 
inhibitors with variations of the tropane ring C-3 substituent, i.e., benztropine and 
its analogs, displayed a considerably altered DUIP as a function of the D79E 
mutation.  A single conservative amino acid replacement thus distinguished 
structural requirements for benztropine function relative to those for all other 
classical DAT inhibitors.  Thus, it is possible to delineate the mechanism of action 
of this DAT inhibitor, which has a low abuse liability, using DAT mutagenesis and 
other structure-function studies.  The development of drugs, including cocaine 
and benztropine analogs, that inhibit DAT and yet display a distinct behavioral 
profile from cocaine in animal models (Newman et al., 1994; Newman and 
Kulkarni, 2002; Woolverton et al., 2002; Kozikowski et al., 2003) suggest that an 
anti-cocaine medication is attainable.   
The present results also indicate that while apparent binding affinities of 
classic DAT blockers were unchanging at CHO cells stably transfected with the 
wildtype rat DAT, the DUIPs for these inhibitors fluctuated as a function of cell 
passage number.  Manipulation of DAT levels in transiently-transfected COS-7 
cells appeared to influence cocaine DUIP in these cells.  These observations 
suggest that an unidentified cellular agent modulates DAT inhibitor DUIP but not 
binding affinity at the DAT protein. 
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V. APPENDICES 
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Effect of DAT substrates on CHO cells stably expressing WT and D79E DAT.  KM and Ki 
values were derived from experiments incubating the stably transfected cells with nonradioactive 
substrates in the presence of [3H]-dopamine (upper panel) or [3H]-WIN35,428 (lower panel) at 
22OC in KRH/AA buffer.  Values are presented as mean ± S.E.M. for three to six independent 
experiments.  DA, dopamine; NE, norepinephrine; MTA, m-tyramine; PTA, p-tyramine; AMPH, 
amphetamine. 
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Effects of DAT cell surface expression on the DUIP of cocaine.  Cocaine inhibition of [3H]-
dopamine uptake by COS-7 cells transiently transfected with various amounts of a plasmid cDNA 
encoding WT DAT. 
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VII.  ABSTRACT 
 
A long-standing postulate holds that cocaine inhibits DAT-mediated 
dopamine transport via competition with dopamine for formation of an ionic bond 
with the DAT transmembrane 1 aspartic acid residue 79.  A recent study from our 
laboratory indicated that mutation of this aspartate to glutamate (D79E) had little 
or no effect on dopamine affinity or dopamine uptake inhibition potencies for 
WIN35,428 and cocaine, and decreased WIN35,428 affinity by only 3 fold (Wang 
et al., 2003). The study cast doubt on the requirement of a dopamine-D79 ion 
pair, but did not address whether the residue plays a role in recognizing the 
cocaine pharmacophore.  In the present study, DAT inhibitors containing 
variations of three primary components of this pharmacophore- the positively 
charged tropane nitrogen atom, the seven-carbon tropane ring itself, and the 
aromatic substituent at the tropane C-3 position- were assessed for binding 
affinity and dopamine uptake inhibition at the same D79 DAT mutants.  Only 
inhibitors with modifications of the phenyl ring substituent of cocaine, i.e. 
benztropine and its analogs, displayed considerably altered dopamine uptake 
inhibition potency as a function of the D79E mutation.  These observations may 
suggest that the side chain of the D79 residue is important for the recognition of 
the aromatic components of DAT ligands. 
Furthermore, we investigated the influence of cell passage number, the 
density of the cell monolayer and the effect of varying DAT expression levels by 
manipulation of transfection conditions on DAT function.  It was observed that the 
DUIPs of cocaine, mazindol, methylphenidate, and benztropine fluctuated as a 
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function of DAT-CHO cell passage number.  The binding affinities of these DAT 
inhibitors, however, remained static.  Also, the DUIP of cocaine fluctuated as a 
result of variations in DAT cell surface expression.  It is therefore conceivable 
that an unidentified cellular mediator modulates DAT inhibitor DUIP but not 
binding affinity at the DAT protein. 
 
 
 
 
 
 
 
 
 
  
